

Issue 5

CUTTING EDGE

Glaucoma

Access the contents & video on the online portal:



<http://collections.medengine.com/ophthalmology/cutting-edge-glaucoma/>



Springer Healthcare Education


In Primary Open Angle Glaucoma & Ocular Hypertension

Rx BRIMOLOL

Brimonidine Tartrate 0.15% + Timolol Maleate 0.5%

■ Combined power, Greater benefits ■

Brimonidine 0.15% shows equal IOP lowering to Brimonidine 0.2%¹



✦ IOP - lowering effect was maintained over the 3 month with Brimonidine 0.15% and Brimonidine 0.2%

✦ Lower concentration of Brimonidine in Brimonidine 0.15% may lower the incidence of allergic conjunctivitis



CUTTING EDGE

Glaucoma

All rights reserved. No part of this publication may be reproduced, transmitted or stored in any form or by any means either mechanical or electronic, including photocopying, recording or through an information storage and retrieval system, without the written permission of the copyright holder.

Although great care has been taken in compiling the content of this publication, the publisher, its employees and editors/officers are not responsible or in any way liable for the accuracy of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not necessarily reflect the views of the publisher, editor/s, editorial board or authors.

Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned in this publication. The product advertisements published in this reprint have been provided by the respective pharmaceutical company and the publisher, its employees and editors/officers are not responsible for the accuracy of the information.

Online access of this input is provided complimentary along with the print issue.

© Springer Healthcare 2020

November 2020

 **Springer** Healthcare

This edition is published by Springer Nature India Private Limited.
Registered Office: 7th Floor, Vijaya Building, 17, Barakhamba Road, New Delhi 110 001, India.
T: +91 (0) 11 4575 5888
www.springerhealthcare.com

Part of the Springer Nature group

Contents

WHAT'S NEW

1. **Treatment Results in Aphakic Patients with Glaucoma Following Congenital Cataract Surgery** 1
Mine Baris, Elif Demirkilinc Biler, Suzan Guven Yilmaz, et al.
2. **Glaucoma Drainage Devices** 14
James D. Brandt, Naama Hammel, Cecilia Fenerty, Tanya Karaconji

CLINICAL VIGNETTE

3. **Bleb Wall Recession Technique to Repair Giant Bleb Formation After Ahmed Glaucoma Valve Implantation: A Case Report** 51
Kaoru Manabe, Yoshifumi Ikeda, Etsuko Fujihara, Masaki Tanito

Videos available online:

1. Blunt dissection of the correct sub-Tenon's plane may be started with scissors and completed with two squint hooks inserted back-to-back in this pocket and pulled gently apart. (Courtesy of Cecilia Fenerty, MD, FRCOphth and Tanya Karaconji, MD, FRANZCO)
2. Method of inserting a tube into the anterior chamber using a blunt-tipped cannula. The tip of the cannula is firmly engaged onto the cut bevel of the tube and gently inserted through the scleral tunnel taking the tube with it. (Courtesy of Cecilia Fenerty, MD, FRCOphth and Tanya Karaconji, MD, FRANZCO)
3. A long tunnel in the patient's native sclera created using a small mini-crescent blade (1.25 mm in width) that can be used to tunnel in the sclera up to about 2 mm posterior to the limbus, then completing the entry into the eye with a 25-gauge needle. (Courtesy of James D. Brandt, MD)
4. Insertion of the tube of a Baerveldt glaucoma drainage device in an eye with aniridia . The lens is slightly displaced to the nasal side, and insertion of the tube at a tangent avoids contact with the lens. The anterior chamber infusion maintains the anterior chamber and constant intraocular pressure throughout the procedure. (Courtesy of Cecilia Fenerty, MD, FRCOphth and Tanya Karaconji, MD, FRANZCO)
5. Surgical video of the bleb wall recession technique.

Step by step procedure for online viewing:

1. Go to <http://collections.medengine.com/ophthalmology/cutting-edge-glaucoma> or scan QR code.
2. Web page of the issue will open on the screen.
3. View and read the PDF version and watch the videos online.
4. The PDF file can be downloaded too for offline reading.



Treatment Results in Aphakic Patients with Glaucoma Following Congenital Cataract Surgery

Mine Baris, Elif Demirkilinc Biler, Suzan Guven Yilmaz, Halil Ates, Onder Uretmen, Suheyila Kose

Abstract

Purpose: To evaluate the clinical findings and possible risk factors of patients with aphakic glaucoma following congenital cataract surgery and identify the factors affecting response to glaucoma treatment.

Methods: A retrospective chart review of 173 patients was performed who underwent congenital cataract surgery before the age of 12 months and 40 eyes of 25 patients with aphakic glaucoma were enrolled. Age of the patients at the time of the cataract surgery, postoperative complications, additional ocular pathologies and the type of glaucoma treatment needed were investigated.

Results: Mean age of 25 patients at the time of cataract surgery was 3.31 ± 2.28 (range 1–11) months with a mean follow-up period of 79 ± 30.5 (32–176) months. Out of 40 eyes, medical therapy was effective in 20 (50%) eyes, whereas 20 (50%) eyes needed surgery for glaucoma. In these 20 eyes, 6 (30%) eyes underwent only 1, 4 (20%) eyes underwent 2 and 10 (50%) eyes underwent 3 or more procedures. Age at the time of cataract surgery, pupillary membrane formation and additional ocular pathologies were not significantly associated both with the need for glaucoma surgery or the number of operations ($p \geq 0.05$).

Conclusion: Aphakic glaucoma following congenital cataract surgery is a serious complication which requires surgery in half (50%) of the patients. Usually, more than one surgical procedure (70%) is needed. It can be detected even years after cataract surgery (range 0.3–94 months), so long-term careful follow-up is necessary.

Keywords: Aphakic glaucoma, Congenital cataract, Glaucoma surgery

Introduction

Aphakic glaucoma (AG) is one of the most important and common complications of congenital cataract surgery (CCS). The incidence of this glaucoma type ranges from 0.9 to 32% [1, 2]. Possible underlying mechanisms include chronic trabeculitis due to postoperative inflammation or chemical factors from the vitreous. AG may also be a component of a single syndrome, the mechanism that leads to cataract formation may also decrease the aqueous outflow from the trabecular meshwork, resulting in chronic open-angle glaucoma [3]. The incidence of early postoperative AG due to pupillary block is decreasing thanks to improved surgical techniques [4]. But complete prevention of AG is not possible. Today, the most common postoperative glaucoma type after CCS is late onset open-angle glaucoma [5]. Management of AG is challenging. While medical treatment should be tried first to lower the intraocular pressure (IOP), surgical procedure is often required to control it [6].

There are many studies investigating the risk factors for glaucoma development following congenital cataract surgery such as age at the time of operation and IOL implantation [7]. However, there are very few studies about the risk factors affecting the results of glaucoma surgery in AG patients [8]. Since it is known that glaucoma surgery has a poor success rate in younger ages, having a perspective about these factors might help us choosing the best treatment option for each patient individually.

The purpose of this study was to evaluate clinical findings, possible risk factors and the medical and surgical treatment results of paediatric AG patients and determine the factors affecting response to glaucoma treatment.

Materials and Methods

We retrospectively reviewed the medical charts of all 284 aphakic eyes of 173 consecutive congenital cataract patients that underwent standard lensectomy and anterior vitrectomy operation before the age of 12 months and followed up for at least 24 months regularly. Forty eyes of 25 patients with aphakic glaucoma were enrolled in the study. The cases with glaucoma diagnosis prior to lensectomy or with independent risk factors for the development of glaucoma such as anterior segment dysgenesis or severe microphthalmia and the patients with previous laser treatment and/or ocular surgery apart from cataract extraction were excluded. Demographic features, clinical course and characteristics, complications and visual outcomes were noted. Lensectomy related information such as age at lensectomy, surgical technique, surgeon, intraoperative and postoperative complications and postoperative medications were also collected. All patients underwent an overall ophthalmic examination, including slit-lamp biomicroscopy, IOP measurement, gonioscopy with Swan Jacob lens and fundus examination through a dilated pupil.

Measurement of best-corrected visual acuity (BCVA) was performed in all cooperative children. Diagnosis of aphakic glaucoma was mainly based on IOP greater than 25 mmHg or a lower pressure associated with one or more of the following findings in the absence of other causes of glaucoma: corneal oedema/enlargement, progressive optic disc cupping defined as an increase

of ≥ 0.2 in the cup-to-disc ratio, asymmetric progressive myopic shift outside the normal limits with the presence of enlargement of the corneal diameter and/or axial length [5, 9–11]. IOP was measured by Tono-Pen AVIA® (Reichert Inc, USA) or a Perkins tonometer (Haag-Streit, Bern, Switzerland); corneal diameter was measured by caliper; and CCT was measured using iPac® pachymeter (Reichert Inc, USA) under inhalation anaesthesia with sevofluran. In our study, all IOP measurements were obtained in first 2 min of anaesthesia and this excludes the possibility of false low results [12, 13]. Anti-glaucomatous treatment modalities and the treatment responses were evaluated. The following parameters were also investigated: age at the time of cataract surgery, visual outcome, post-treatment IOP, postoperative complications, optic disc abnormalities, number of re-operations, presence of systemic and ocular anomalies.

Initial treatment was prescribing anti-glaucoma medications in all of the eyes with AG. The eyes with progressive buphthalmos or glaucomatous optic neuropathy coupled with uncontrolled IOP despite the use of maximum anti-glaucoma medications underwent glaucoma surgery. Trabeculectomy was the first applied procedure in all eyes [14]. Success was defined as if IOP is less than 21 mmHg (complete success without any anti-glaucoma medications and qualified success with anti-glaucoma medications) and if stable corneal diameter was maintained with no further optic disc cupping in the absence of any devastating complication throughout the follow-up period [15, 16].

The criteria for re-operation were progressive myopic shift and/or increase in corneal diameter despite of maximum anti-glaucomatous treatment, progressive increase in cup/disc ratio of optic disc and increase in IOP [17].

Control visits were scheduled as every 3–4 months, and all parameters were evaluated in each visit. Drainage device implantation (Ahmed glaucoma valve) and cyclodestructive surgeries were second- and third-order surgeries, respectively. Congenital cataract surgeries were performed by two of the authors (OU and SK), and glaucoma surgeries were performed by one of the authors (HA). The surgical methods were similar in all cases.

Data collection for this study has been approved by University Local Research Ethics Committee. The study protocol adhered to the Declaration of Helsinki for research involving human participants.

Statistical analysis was performed with SPSS for Windows Version 15.0 (SPSS Inc., Chicago, IL, USA). All data were reported as averages \pm standard deviations (SD). Chi-square, *t* test and Pearson correlation test were used. *p* value of 0.05 or less was considered as statistically significant.

Results

Out of 284 aphakic eyes, 40 (14%) eyes of 25 patients (15 male, 10 female) were diagnosed as AG. The mean age at the time of cataract extraction was 3.31 ± 2.28 (range 1–11) months, and the mean follow-up period was 79 ± 30.5 (32–176) months. Cataract surgery was performed by one of the authors. The operative technique was same in all cases including corneal incision, anterior capsulorrhexis, hydrodissection, aspiration of lens material and posterior capsulorrhexis together with anterior vitrectomy. No surgical or postoperative complications occurred in any of

the eyes. After lensectomy, eyes were treated with corticosteroids, antibiotics and cycloplegics for 1–2 months postoperatively. There were no known cases of corneal decompensation or endophthalmitis. Fifteen (60%) patients had bilateral lensectomy and developed aphakic glaucoma in both eyes. Seven (28%) patients had unilateral lensectomy and developed aphakic glaucoma in only that operated eye. Three (12%) patients had bilateral lensectomy and developed aphakic glaucoma in only one eye at last follow-up. Mean interval between cataract surgery and development of glaucoma was 8.4 ± 23.1 (range 0.3–94) months. Accompanying ocular malformations were detected in 6 (15%) eyes which were microcornea in 5 eyes and persistent foetal vasculature (PFV) in 1 eye. As systemic diseases, 1 patient had Down's syndrome, 1 patient had respiratory distress due to prematurity without accompanying retinopathy of prematurity and 1 patient had thalassaemia major.

All of 3 patients with systemic diseases underwent unilateral cataract surgery. Secondary intraocular lens (IOL) implantation was not performed in any of the eyes during the follow-up period. Demographic data and clinical characteristics of patients and the postoperative complications after congenital cataract surgery are outlined in Table 1.

Pupillary membrane formation was observed in 19 (47.5%) eyes, and mean duration of time between cataract surgery and membrane formation was 95 days (range 10–180). Topical steroids were used as initial treatment in all eyes, and the membrane was resolved in 7 (36.8%) eyes. The remaining 12 eyes, in which the membrane was not resolved with medical treatment (63.2%), underwent membranectomy. Additional peripheral iridotomy was also performed in one of them, and glaucoma surgery was required in 5 cases due to unresponsive topical anti-glaucomatous therapy.

Closed iridocorneal angle was detected in 4 (10%) eyes, and open iridocorneal angle was observed in 36 (90%) eyes. Medical treatment was effective by reducing increased IOP to normal levels and preventing glaucomatous changes in 20 (50%) eyes. On the other hand, due to progressive buphthalmos or glaucomatous optic neuropathy accompanying uncontrolled IOP, 20 (50%) eyes subsequently underwent glaucoma surgery. Number of glaucoma medications prescribed for the patients treated with only antiglaucoma drops and number of glaucoma surgeries performed in patients who needed glaucoma surgery in addition to medical treatment are summarized in Table 2. In all the eyes with additional ocular pathologies, medical treatment was effective and none of them required glaucoma surgery. Except one eye (5%) among the eyes that needed glaucoma surgery, all eyes subsequently required additional medical therapy during the follow-up period.

In patients with medical treatment, dorzolamide–timolol combination was the most frequently used medication and prostaglandin analogues were the second medical treatment choice. Mean preoperative IOP of medically treated eyes was 25.1 ± 1.22 , and mean postoperative IOP was 16.8 ± 3.2 mmHg ($p = 0.02$, paired sample *t* test). In patients who needed glaucoma surgery, the most frequently and initially applied procedure was trabeculectomy (all 20 eyes had trabeculectomy at least once). Mitomycin C (MMC) (0.2 mg/ml for 4 min) was used in all trabeculectomy procedures. Drainage device implantation (Ahmed glaucoma valve; 6 eyes) and cyclodestructive surgeries (9 eyes) were performed as second- and third-step procedures.

Table 1: Demographic data and clinical characteristics of patients at the time of glaucoma diagnosis.

Characteristics (40 eyes of 25 patients)	
Sex, number of patients (%)	
Female	10 (40%)
Male	15 (60%)
Age at cataract surgery, months	
Mean \pm SD (range)	3.31 \pm 2.28 (1–11)
Interval between cataract surgery and glaucoma diagnosis, months	
Mean \pm SD (range)	8.4 \pm 23.1 (0.3–94)
Laterality of glaucoma, number of patients (%)	
Unilateral	10 (40%)
Bilateral	15 (60%)
Coexisting systemic disease, number of patients (%)	
Down syndrome	1 (4%)
Respiratory distress (prematurity)	1 (4%)
Thalassaemia major	1 (4%)
Coexisting ocular pathology, number of eyes (%)	
Microcornea	5 (12.5%)
Persistent foetal vasculature	1 (2.5%)
Complications after congenital cataract surgery, number of eyes (%)	
Pupillary membrane	19 (47.5%)
Residual lens material	4 (10%)
Pupillary block	4 (10%)
Posterior synechiae	6 (15%)
IOP	
Mean \pm SD (mmHg)	29.8 \pm 14.8
Corneal diameter	
Mean \pm SD (mm)	10.5 \pm 1.06

The mean IOP of all study eyes decreased significantly from 29.8 \pm 14.8 mmHg (23–46 mmHg) to 17.3 \pm 2.1 mmHg (12–30 mmHg) after glaucoma treatment over a mean follow-up time of 79 (range 32–176) months ($p = 0.01$, paired sample t test). There was no statistically significant difference in corneal diameter between pre- and post-glaucoma treatment (10.5 \pm 1.06 mm and 11.3 \pm 0.3 mm, respectively) ($p = 0.08$, paired sample t test). The mean cup/disc ratio at the time of glaucoma diagnosis was 0.4 \pm 0.3, whereas the mean postoperative cup/disc ratio was 0.6 \pm 0.3. Pale optic discs were observed in 9 eyes. Pre-treatment CCT measurements could

Table 2: Treatment features of aphakic glaucoma eyes.

Only medical treatment (20 eyes)		Glaucoma surgery (20 eyes)	
Medications, n (%)	Eyes, n (%)	Surgeries n (%)	Eyes, n (%)
1 Drug	15 (75)	1 Operation	6 (30)
2 Drugs	4 (20)	2 Operations	4 (20)
3 Drugs	1 (5)	≥ 3 Operations	10 (50)

Table 3: Complications following glaucoma surgery.

Complications	Eyes, n (%)
Shallow anterior chamber	2 (10)
Hypotony	2 (10)
Bullous keratopathy	1 (5)
Choroidal detachment	1 (5)
Implant exposure	1 (5)

not be obtained from the all patients, but the mean CCT measurements were noted as $626.0 \pm 48.4 \mu\text{m}$ at the last follow-up visit. Visual acuity (in Snellen chart) was evaluated overall in 25 eyes of 14 children that were able to cooperate, and the mean final BCVA was 0.28 ± 0.16 (20/70 \pm 20/125).

Complications seen after glaucoma surgery are listed in Table 3. Devastating complications such as retinal detachment and endophthalmitis were not observed in any of the cases. Choroidal detachment in one eye was treated successfully with systemic corticosteroids. Eyes with shallow anterior chamber ($n = 2$; 10%) and hypotony ($n = 2$; 10%) were covered with medical treatment (topical steroids) in 3 weeks and did not require any surgery. In one eye with implant exposure, revision surgery was performed with conjunctival flap.

Age at the time of cataract surgery, pupillary membrane formation and additional ocular pathologies were not found to be significantly associated with the need for glaucoma surgery (respectively $r = 0.25$, $p = 0.9$ and $p = 5.1$; Pearson’s correlation analysis and Chi-square test) or the number of operations (respectively $r = -0.17$, $p = 0.4$ and $p = 4.0$; Pearson’s correlation analysis Chi-square test) (Table 4).

Discussion

Aphakic glaucoma is one of the major complications of congenital cataract surgery. Treatment success rates are not satisfying, and there is still lack of adequate information, especially about the factors effecting the treatment results. In this study, our aim was to evaluate the factors that might have an affect on response to treatment and also prognosis.

In our study, the rate of AG was 14% with a mean follow-up period of 79 months. Similar results were reported by Mills *et al.* [2] as 14.4% with a mean follow-up time of 5.8 years; Keech

Table 4: Statistical relations between glaucoma treatment and clinical features.

	Age at cataract surgery (<i>r</i> value)	Pupillary membrane formation (<i>p</i> value)	Additional ocular pathologies (<i>p</i> value)
Need for glaucoma surgery	0.25*	0.9**	5.170**
Number of glaucoma surgeries	- 0.176*	0.4**	4.0**

*Pearson correlation analysis

**Chi-square test

et al. [9] as 12.5% with a mean follow-up time of 3.7 years; and Magnusson *et al.* [7], as 12% with a mean follow-up time of 9.2 years. The incidence of acute postoperative angle closure glaucoma was decreased with the modern surgical techniques in congenital cataract surgery; however, the ratio of AG remains almost the same as reported in the literature [4].

Most common type of the glaucoma in our study was observed as open-angle glaucoma in 90% of the eyes in concordance with the findings of the Infant Aphakia Treatment Study (IATS) that was reported the open-angle glaucoma rate as 95% [5]. Some ocular anomalies such as PFV and microcornea are shown to have a relationship with development of AG in the previous studies [2], but according to our study results, they did not effect the treatment response negatively. The eyes with ocular pathologies (5 eyes with microcornea and 1 eye with PFV) in our study were all responded to medical treatment with topical antiglaucomatous drops and none of them needed surgery. The low number of cases with such anomalies in our study might be the reason why there were no negative impact observed. In IATS reports, PFV also did not influence the risk of developing glaucoma or glaucoma suspect, but having a corneal diameter of 10 mm or less seemed to increase the risk of diagnosing as glaucoma or glaucoma suspect [5]. Nevertheless, our finding suggested us not to be pessimistic about AG treatment in those eyes (Table 5).

Young age at the time of cataract surgery, as another possible risk factor, was also reported to be responsible for AG development in the literature [2, 7] as it was in our study. Out of 40 eyes, 36 (90%) eyes were operated in the first 6 months and 26 (65%) eyes were operated in the first 3 months of life. However, age at the time of cataract surgery was not found to be a negative prognostic factor for treatment of AG and not significantly associated both with the need for glaucoma surgery or the number of operations. Khan *et al.* reported 2 peak incidences of relative risk for later aphakic glaucoma as a function of age at the time of cataract surgery, one within the first month of life and the second at 5–6 months of life, but these intervals did not correlate with postsurgical complications that required re-operation [18].

Pupillary membrane formation was observed in 19 (47.5%) eyes in our study and 12 (63.2%) of them needed membranectomy as treatment. In the study of Zetterberg *et al.* [8], 3 eyes (13%) out of 23 AG eyes needed surgery for pupillary membrane. The higher rate in our study might be the result of younger age (mean; 3.31 ± 2.28 months) at the time of cataract surgery and maybe due to the presence of more inflammation. On the other hand, pupillary membrane formation was not found to be statistically related with anti-glaucoma treatment response or number of glaucoma surgeries.

Table 5: Summary.

Patient no.	Eye	Age during cataract surgery	Ocular anomalies	Complications of cataract surgery (treatment)	Glaucoma treatment modality	Complications of glaucoma surgery	Final BCVA
1	R	1.5	None	Residual lens material	Surgical (2 operations)	–	NA
	L	1.5	None	None	Medical (1 drug)	–	NA
2	R	2	None	Pupillary membrane (surgical)	Medical (1 drug)	–	0.2
	L	2	None	Pupillary membrane (surgical), posterior synechiae	Medical (1 drug)	–	0.2
3	L	7	None	None	Medical (3 drugs)	–	0.2
4	R	4	None	None	Medical (1 drug)	–	0.4
	L	4	None	Pupillary membrane (surgical), pupillary block	Surgical (1 operation)	–	0.3
5	R	4	None	Pupillary membrane (medical), pupillary block	Medical (2 drugs)	–	0.05
	L	4	None	None	Medical (2 drugs)	–	0.3
6	R	4	None	None	Surgical (3 operations)	–	0.3
	L	4	None	Pupillary membrane (medical), pupillary block	Surgical (3 operations)	–	0.3
7	R	2	None	None	Surgical (6 operations)	Implant exposure	0.1
	L	2	None	Residual lens material	Surgical (6 operations)	–	0.1
8	L	5	None	Pupillary membrane (surgical)	Surgical (1 operation)	–	0.6
9	R	1.5	None	Pupillary membrane (medical)	Surgical (2 operations)	Shallow anterior chamber	NA

continued...

...continued

10	R	3	None	None	Medical (1 drug)		0.3
	L	3	None	Posterior synechiae	Medical (1 drug)		0.4
11	R	1.5	None	None	Surgical (3 operations)	Bullous keratopathy	0.05
	L	1.5	None	Pupillary membrane (medical)	Surgical (3 operations)	Hypotony	0.05
12	R	4	None	Pupillary membrane (medical), pupillary block	Surgical (2 operations)	Choroidal detachment	NA
	L	4	None	Pupillary membrane (medical)	Surgical (3 operations)		NA
13	L	3	None	Pupillary membrane (surgical)	Medical (1 drug)		0.4
14	R	3	Microcornea	None	Medical (1 drug)		NA
	L	3	Microcornea	Pupillary membrane (surgical)	Medical (1 drug)		NA
15	R	3	Microcornea	Pupillary membrane (surgical)	Medical (1 drug)		NA
	L	3	Microcornea	Pupillary membrane (surgical)	Medical (1 drug)		NA
16	R	1	None	Pupillary membrane (surgical)	Surgical (1 operation)		NA
	L	1	None	Pupillary membrane (medical), posterior synechiae	Medical (1 drug)		0.6
17	R	3	None	None	Medical (1 drug)		0.5
	L	3	None	Pupillary membrane (surgical)	Medical (1 drug)		0.5
18	R	1	None	Pupillary membrane (surgical)	Surgical (4 operations)		NA

continued...

...continued

	L	1	None	None	Surgical (3 operations)		NA
19	R	4	None	None	Surgical (1 operation)		0.3
20	L	7	None	Pupillary membrane (surgical), posterior synechiae	Surgical (2 operations)		NA
21	L	3	None	None	Surgical (8 operations)	Shallow ant. chamber, hypotony	NA
22	R	2	PFV	Residual lens material	Medical (1 drug)		NA
23	L	11	Microcornea	Posterior synechiae	Medical (2 drugs)		NA
24	R	1	None	None	Surgical (1 operation)		0.2
	L	1		None	Surgical (1 operation)		0.2
25	L	11	None	Residual lens material, posterior synechiae	Medical (2 drugs)		NA

Mean duration of time between congenital cataract surgery and development of AG was 8.4 ± 23.1 (range 0.3–94) months. Magnusson *et al.* [7] reported onset of glaucoma as a median of 6.2 months (187 days) following cataract surgery. Zetterberg *et al.* [8] reported the interval between congenital cataract surgery and AG diagnosis as a mean of 9.5 months. The mean duration between cataract removal and diagnosis of glaucoma was reported as much as 7 years in another study [19]. In IATS, it was proposed that the risk of glaucoma was 17% and the risk for developing glaucoma or glaucoma suspect was 31% at 4.8 years following cataract surgery which was performed between 1 and 6 months of life [5]. All these findings were suggested that AG can occur at any age and long-term follow-up is important.

Among the eyes that were treated with antiglaucoma medications only, 15(75%) eyes needed only 1 medication, 4 eyes (20%) needed 2 medications and 1(5%) eye needed 3 medications. Bhola *et al.* [19] reported that 20 eyes (36%) required 2 or less medications, 18 eyes (33%) required maximum 3 medications and 17 eyes (31%) required 4 or more medications for more than 6 months.

In our study, among the eyes that required surgery, 30% required only 1; 20% needed 2 and 50% needed 3 or more operations. Similarly, Zetterberg *et al.* [8], reported their ratios as 35%

needed 1, 35% of eyes required 2 and 30% of eyes needed more than 2 procedures. Bhola *et al.* reported as 27% of all study eyes needed 1 or more surgery. In their study, among the surgically treated eyes, 40% required only 1 surgical procedure, 47% required 2–3 operations and 13% required more than 4 procedures [19].

Trabeculectomy with MMC was the first line of treatment in surgical management of AG. However, it is known that trabeculectomy is not very successful in younger ages, because of increased fibrotic activity and rapid wound healing response [20]. In our study, trabeculectomy with MMC alone was successful in 6 eyes that did not require drainage device implantation or cyclodestructive surgery. Among these eyes, only 1 eye had a stable IOP under 21 mmHg without any anti-glaucoma medication and with no glaucomatous optic disc changes (complete success). Azuaro *et al.* [12] also reported the probability of having IOP 21 mmHg as 0% without any anti-glaucoma medication and with clinically stable glaucoma 1 year after surgery in the 8 (57%) aphakic eyes in their study. Both these findings suggested that glaucoma following congenital cataract surgery is mostly refractory to filtering surgery even with the intraoperative use of MMC.

There are few studies that reported higher success rates with glaucoma drainage devices for refractory glaucoma in paediatric population. Molteno *et al.* [21] and Billson *et al.* [22] reported success rates of 87 and 95%, respectively. Contraindicatory reports also have been published. Coleman *et al.* [23] reported cumulative probability of success 60% at 24 months, while Nesher *et al.* [24] reported a success rate of 59%. The success rates of glaucoma drainage devices in paediatric glaucoma are variable, and there is an absence of prospective randomized clinical trials comparing these devices with trabeculectomy. Considering the complications of drainage device implantation, especially the negative impact on cornea, we prefer trabeculectomy as first-line surgical treatment. We use drainage device implantation (Ahmed valve) in 6 eyes as secondary procedure and observe tube erosion (exposure) as complication in 1 (16.6%) eye.

As for the angle surgeries in AG, Bothun *et al.* reported a 57% success rate with angle surgeries (trabeculotomy 180° and/or goniotomy 180°) in their study of 14 eyes. The mean number of surgeries in that study was 1.3. Success was defined as an IOP of ≤ 24 mmHg with or without topical medication, a lack of sight treating complication and avoidance of trabeculectomy or tube shunt, and treatment success rate after 1 surgery was 42.9% (all eyes had trabeculotomy) [25].

AG is a challenging condition that mostly requires surgery and multiple procedures might be needed. But despite of high surgery rates, the final best-corrected visual acuity was ≥ 0.3 in 13 (32.5%) eyes and ≥ 0.1 in 20 (50%) eyes in our study. In Bhola *et al.*'s study, the final BCVA was reported as $\geq 20/40$. The final BCVA was no light perception in 1 (2.5%) eye and hand motions in other 1 (2.5%) eye. In 15 (37.5%) eyes, BCVA measurements could not be detected because of poor cooperation or pre-verbal ages. These findings showed that the results could be worth the effort and we should not give up on these children.

Limitations of this study were its retrospective design and relatively small number of patients.

In conclusion, the management of glaucoma following congenital cataract surgery is challenging. Risk factors for development of glaucoma are better known than the factors that might affect the response to treatment. More studies are needed to understand these factors and have an opinion about the response to treatment at the beginning.

Compliance with ethical standards

Conflict of interest All authors declare that there is no conflict of interest.

References

1. Rabiah PK (2004) Frequency and predictors of glaucoma after pediatric cataract surgery. *Am J Ophthalmol* 137:30–37.
2. Mills MD, Robb RM (1994) Glaucoma following childhood cataract surgery. *J Pediatr Ophthalmol Strabismus* 31:355–360.
3. Phelps CD, Arafat NI (1993) Open-angle glaucoma following surgery for congenital cataracts. *Arch Ophthalmol* 95:1985–1987.
4. Kirwan C, O'Keefe M (2006) Pediatric aphakic glaucoma. *Acta Ophthalmol Scand* 84:734–739.
5. Freedman SF, Lynn MJ, Beck AD *et al* (2015) Infant aphakia treatment study group. glaucoma-related adverse events in the first 5 years after unilateral cataract removal in the infant aphakia treatment study. *JAMA Ophthalmol* 133:907–914.
6. Asrani SG, Wilensky JT (1995) Glaucoma after congenital cataract surgery. *Ophthalmology* 102:863–867.
7. Magnusson G, Abrahamsson M, Sjöstrand J (2000) Glaucoma following congenital cataract surgery: an 18-year longitudinal follow-up. *Acta Ophthalmol Scand* 78:65–70.
8. Zetterberg M, Nystro'm A, Kalaboukhova L, Magnusson G (2015) Outcome of surgical treatment of primary and secondary glaucoma in young children. *Acta Ophthalmol* 93(3):269–275.
9. Keech R, Tongue A, Scott W (1989) Complications after surgery for congenital and infantile cataracts. *Am J Ophthalmol* 108:136–141.
10. Kirwan C, Lanigan B, O'Keefe M (2010) Glaucoma in aphakic and pseudophakic eyes following surgery for congenital cataract in the first year of life. *Acta Ophthalmol* 88(1):53–59.
11. Beck AD, Freedman SF, Lynn MJ, Bothun E, Neely DE, Lambert SR (2012) Infant aphakia treatment study group. glaucoma-related adverse events in the infant aphakia treatment study: 1-year results. *Arch Ophthalmol* 130(3):300–305.
12. Mandal AK, Chakrabarti D (2011) Update on congenital glaucoma. *Indian J Ophthalmol* 59:148–157.
13. Blumberg D, Congdon N, Jampel H *et al* (2007) The effects of sevoflurane and ketamine on intraocular pressure in children during examination under anesthesia. *Am J Ophthalmol* 143:494–499.
14. Azuara-Blanco A, Wilson RP, Spaeth GL, Schmidt CM, Augsburger J (1999) Filtration procedures supplemented with mitomycin C in the management of childhood glaucoma. *Br J Ophthalmol* 83:151–156.
15. Javaram H, Scawn R, Pooley F *et al* (2015) Long term outcomes of trabeculectomy augmented with mitomycin C undertaken within the first 2 years of life. *Ophthalmology* 122(11):2216–2220.
16. Neustein RF, Bruce BB, Beck AD (2016) Primary congenital glaucoma versus glaucoma following congenital cataract surgery: comparative clinical features and long term outcomes. *Am J Ophthalmol* 170:214–222.
17. Roche O, Beby F, Parsa A *et al* (2007) Nonpenetrating external trabeculectomy for congenital glaucoma: a retrospective study. *Ophthalmology* 114:1994–1999.
18. Khan AO, Al-Dahmesh S (2009) Age at the time of cataract surgery and relative risk of aphakic glaucoma in nontraumatic infantile cataract. *J AAPOS* 13:166–169.
19. Bhola R, Keech RV, Olson RJ, Peterson DB (2006) Long term outcome of pediatric aphakic glaucoma. *J AAPOS* 10:243–248.

20. Mandal AK, Bagga H, Nutheti R, Gothwal VK, Nanda AK (2003) Trabeculectomy with or without mitomycin-C for pediatric glaucoma in aphakia and pseudophakia following congenital cataract surgery. *Eye* 17:53–62.
21. Molteno ACB, Ancker E, Biljon GV (1984) Surgical technique for advanced juvenile glaucoma. *Arch Ophthalmol* 102:51–57.
22. Billson F, Thomas R, Alward W (1989) The use of twostage Molteno implants in developmental glaucoma. *J Pediatr Ophthalmol Strabismus* 26:3–8.
23. Coleman AL, Smyth RJ, Wilson MR, Tam M (1997) Initial clinical experience with the Ahmed glaucoma valve implant in pediatric patients. *Arch Ophthalmol* 115:186–191.
24. Nesher R, Sherwood MB, Kass MA, Hines JL, Kolker AE (1992) Molteno implants in children. *J Glaucoma* 1:228–232
25. Bothun ED, Guo Y, Christiansen SP *et al* (2010) Outcome of angle surgery in children with aphakic glaucoma. *J AAPOS* 14:235–239.

Source: Baris, M., Biler, E.D., Yilmaz, S.G. *et al.* Treatment results in aphakic patients with glaucoma following congenital cataract surgery. *Int Ophthalmol* **39**, 11–19 (2019). <https://doi.org/10.1007/s10792-017-0777-y>. ©Springer Science+Business Media B.V., part of Springer Nature 2017.

Glaucoma Drainage Devices

James D. Brandt, Naama Hammel, Cecilia Fenerty, Tanya Karaconji

Introduction

The treatment of primary congenital glaucoma (PCG) and the many secondary forms of glaucoma in childhood was revolutionized in the 1940s with the introduction of targeted surgery of the anterior chamber angle: goniotomy *ab-interno* [1] and trabeculotomy *ab-externo* [2, 3]. Retrospective studies of both trabeculotomy and goniotomy in patients with PCG demonstrate success rates as high as 75–90%. However, even in the best of hands, some 20% or more of primary angle surgeries eventually fail, due to the underlying structural defect, the severity of the glaucoma at presentation, or the underlying diagnosis. Secondary glaucomas presenting in infancy such as aniridia, Axenfeld-Rieger anomaly, Peters anomaly, and glaucoma following cataract surgery (GFCS) often respond poorly if at all to primary angle surgery. When angle procedures like goniotomy or trabeculotomy fail, cannot be performed due to abnormal anatomy, or are felt unlikely to succeed based on the underlying presentation, surgeons are then confronted with choosing an alternative. One increasingly attractive option is the implantation of a glaucoma drainage device (GDD). This chapter will review the current status of GDDs in the management of childhood glaucoma including general principles of these devices, surgical techniques, and a review of the current pediatric GDD literature. We hope to provide useful guidance to surgeons confronting this clinical challenge.

All GDDs share a common design – they employ a biocompatible silicone tube placed in the anterior chamber (AC) or vitrectomized posterior chamber in order to shunt aqueous humor to the subconjunctival space [4]. This potential space between the sclera and the overlying Tenon capsule and conjunctiva is then maintained by an external biocompatible “plate” made of silicone or acrylic which varies in surface area. Once healing has occurred, the IOP-lowering effect of a GDD is roughly proportional to the inner surface area of the capsule surrounding the plate [5, 6].

J. D. Brandt (✉), **N. Hammel**

Department of Ophthalmology and Vision Science, University of California, Davis, Sacramento, CA, USA
e-mail: jdbrandt@ucdavis.edu

C. Fenerty, T. Karaconji

Manchester Royal Eye Hospital, University of Manchester, Manchester, UK

History

The first purpose-designed GDD was that of Molteno [7], introduced in the early 1970s. In the first iteration of his procedure, the circular acrylic plate was sutured to the equatorial sclera and the tube tucked out of the way for subsequent retrieval (Stage 1). Some weeks later, after a fibrous capsule had formed around the plate, the tube was then retrieved (without violating the plate capsule) and inserted into the eye to drain aqueous humor (Stage 2). Molteno subsequently described the use of a Vicryl® (polyglactin) (Ethicon Somerville NJ, USA) tie to temporarily occlude the tube long enough for a capsule to develop around the equatorial implant [8], thus avoiding a two-stage procedure. In either case, glaucoma medications are used to lower intraocular pressure (IOP) until the device is fully functioning some 6 to 8 weeks later.

Currently available GDDs are listed in Table 1 and can broadly be categorized based by whether they are valved (e.g., Ahmed glaucoma valve) or non-valved designs (e.g., Molteno™, Baerveldt®, and Aurolab aqueous drainage implant devices) and then further categorized by plate surface area. Non-valved implants must be temporarily occluded to prevent early hypotony until sufficient fibrosis has developed around the plate to prevent hypotony; valved devices allow flow immediately after surgical implantation.

Considerations for Surgeons Experienced with GDD Surgery in Adults

It's often stated that children are not simply little adults, and certainly their eyes don't behave like little adult eyes. Glaucoma surgeons experienced in placing GDD in adult eyes must modify their usual surgical technique for the pediatric eye. Covered in more detail in this chapter, the following is a partial listing of things to note when tackling these cases:

- *Consider ocular size when choosing a glaucoma implant.* An adult-sized implant can usually be placed in a buphthalmic eye, but in nanophthalmic or microphthalmic eyes, a shorter implant must be chosen to avoid impinging on the optic nerve.
- *The sclera of buphthalmic eyes is very thin.* Suture passes can easily perforate the sclera leading to a retinal detachment. A longer, shallow pass may be necessary to adequately secure the implant in place.
- *Ocular growth must be accounted for in selecting tube position and length.* Around 3 millimeters of tube length must remain in the AC to accommodate for progressive buphthalmos or normal ocular growth in young children. Tube retraction in the growing eye is a late complication that can generally be avoided.
- *Forward tube movement is common.* In the pediatric eye, tubes tend to straighten out over time and will erode through overlying sclera and peripheral cornea. It is generally best to position AC tube entry as posterior as possible away from the cornea (sometimes through a surgical iridectomy) to avoid late corneal complications.
- *Pars plana placement may be considered in aphakic and pseudophakic eyes.* In children, placement in the pars plana must be accompanied by a meticulous and thorough vitrectomy. Late occlusion with vitreous remnants and retinal detachment are common (~ 20%) [9].

Table 1: Currently marketed glaucoma drainage devices.

Name	Type	Model	Materials	Valve/drainage mechanism	Plate surface area (mm ²)	Manufacturer	FDA/CE approval status	Website
Ahmed glaucoma valve	Valved	FP7 (flexible plate)	Medical-grade silicone	Elastomer membrane	184	New World Medical	FDA and CE	http://www.newworldmedical.com/product-fp7
		FP8 (flexible plate – pediatric)	Medical-grade silicone	Elastomer membrane	102	New World Medical	FDA and CE	http://www.newworldmedical.com/product-fp8
		S2	Medical-grade polypropylene	Elastomer membrane	184	New World Medical	FDA and CE	http://www.newworldmedical.com/product-s2
		S3 (pediatric)	Medical-grade polypropylene	Elastomer membrane	85	New World Medical	FDA and CE	http://www.newworldmedical.com/product-s3
Baerveldt® glaucoma implant	Non-valved	BG 103–250 glaucoma implant	Medical-grade silicone	Open tube	250	Johnson & Johnson Vision	FDA and CE	https://surgical.jnjvision.com/us/iols/other/baerveldt-glaucoma-implants
		BG 101–350 glaucoma implant	Medical-grade silicone	Open tube	350	Johnson & Johnson Vision	FDA and CE	
		Pars plana BG 102–350 glaucoma implant	Medical-grade silicone	Open tube with Hoffman elbow	350	Johnson & Johnson Vision	FDA and CE	
Molteno™	Non-valved	Molteno™ SS	Medical-grade acrylic	Open tube	185	Molteno Ophthalmic	FDA and CE	https://www.molteno.com/molteno-glaucoma-drainage-devices
		Molteno™ SL	Medical-grade acrylic	Open tube	245	Molteno Ophthalmic	FDA and CE	
		Pediatric/microphthalmic P1	Medical-grade acrylic	Open tube	80	Molteno Ophthalmic	FDA and CE	
Aurolab aqueous drainage implant (AADI)	Non-valved		Silicone	Open tube	350	Aurolab (a manufacturing division of Aravind Eye Institute, Madurai, India)	CE	http://www.aurolab.com/glaucoma-shunt.asp

FDA US Food and Drug Administration, CE European Commission

Specific Glaucoma Drainage Devices

Molteno™ Glaucoma Drainage Devices

The Molteno drainage implant was the pioneering GDD first described in 1969 [7]. It provided the foundation on which all of the currently available GDDs are based. The Molteno™ implant is a non-valved device consisting of a silicone tube attached to an end plate placed 9–10 mm posterior to the limbus within the subconjunctival space. The plate is sutured to the sclera and covered by a thick flap of Tenon tissue and conjunctiva. A permeable fibrovascular bleb forms over the plate, the surface area of which contributes to the amount of aqueous drainage and the final level of IOP [10] along with the thickness of the bleb capsule.

The original Molteno™ implant consisted of a single 13 mm diameter plate molded from acrylic with a surface area of 135 mm². The single plate is inserted between two rectus muscles in the chosen quadrant. The double-plate Molteno™ implant was introduced in 1981 and consists of two plates, one of which is attached to the silicone tube in the AC, while a second tube connects the two plates forming a total surface area of 270 mm².

Currently marketed (Molteno Ophthalmic, Ltd., Dunedin, New Zealand) Molteno™ implants (Fig. 1) are the Molteno3™ S-Series, the SS (185 mm²), and SL (245 mm²) models, both designed




Fig. 1: (a) The Molteno3™ S-Series of glaucoma drainage devices; the model SS (right) has a surface area of 185 mm², the model SL (left) has a surface area of 245 mm²; (b) diagram of model SS; (c) diagram of model SL; (d) diagram of model P1. Model P1 is designed for very small pediatric or nanophthalmic eyes and has a surface area of 80 mm². (Courtesy of Molteno Ophthalmic Ltd., Dunedin, New Zealand)

for single-quadrant placement, and the Molteno™ P1 (80 mm²) designed for implantation in eyes with axial lengths shorter than 17 mm.

Baerveldt® Glaucoma Drainage Devices

Introduced in 1990, the Baerveldt® glaucoma implant (BGI) is a non-valved device with a silicone tube attached to one of two sizes of external silicone plate (250 and 350 mm²). The company (Johnson & Johnson Vision, Santa Ana CA, USA) also markets a 350 mm² version for implantation in the pars plana with the tube specially modified with a Hoffman elbow for this purpose. All are designed for surgical implantation in a single quadrant (Fig. 2).

The “wings” of the plate are intended for placement under the adjacent rectus muscles. When positioned in this manner, the front edge of the implant rests approximately 8 mm posterior to the limbus. All BGIs are made of smooth, tumble-polished, pliable medical-grade silicone. Barium is incorporated into the silicone, which results in a white, radio-opaque device. The plates are designed with four holes to allow a tissue “bridge” to develop between the upper and lower surfaces of the eventual capsule to limit the size of the bleb and thus reduce the likelihood of restrictive strabismus and diplopia.




Fig. 2: The Baerveldt® glaucoma implant comes in three models : Model BG 101–350 (a) has a surface area of 350 mm²; Model BT103–250 (b) has a surface area of 250 mm²; Model 102–350 (c) has a surface area of 350 mm² and is designed with a Hoffman Elbow for insertion into the pars plana. (Courtesy of Johnson & Johnson Vision, Santa Ana CA, USA)

Ahmed Glaucoma Valves

The Ahmed glaucoma valve (AGV) received the US Food and Drug Administration (FDA) approval in November 1993. The implant consists of three parts: a plate made of medical-grade silicone, polypropylene, or porous polyethylene, depending on the model; a drainage tube fabricated of medical-grade silicone; and a valve mechanism (Fig. 3). The non-obstructive, self-regulating valve mechanism consists of thin silicone elastomer membranes 8 mm long by 7 mm wide enclosed within Venturi-shaped chamber. The membranes are pretensioned to open and close in response to IOP variations, in the range of 8–12 mmHg, and so reduce the rate of early postoperative hypotony [11, 12]. After implantation, aqueous humor flows into the trapezoidal chamber of the valve.

Aurolab Aqueous Drainage Implant (AADI)

The Aurolab aqueous drainage implant (AADI) was introduced in 2013 by Aurolab (a manufacturing division of Aravind Eye Institute, Madurai, India). The AADI is a low-cost (~ US\$50), non-valved GDD designed to replicate the BGI with a 350 mm² plate area (Fig. 4). Professor George Baerveldt authorized the use of his very successful design, and the device was manufactured in collaboration with the Bascom Palmer Eye Institute, Miami, Florida. Originally designed for use in India and other low-resourced countries, the device has received CE (European Commission) marking approval and is becoming broadly available in those countries that accept the CE mark for regulatory approval. It is not approved by the FDA and is therefore unavailable in the United States. Kaushik and colleagues [13] recently reported a prospective interventional study on 34 eyes of 31 children with refractory childhood glaucoma in which the AADI was implanted.




Fig. 3: Ahmed glaucoma valve FP7 (a) is a valved silicone glaucoma drainage device (GDD) implant with a surface area of 184 mm²; the Ahmed glaucoma valve FP8 (b) is a GDD designed for small pediatric or nanophthalmic eyes, with a surface area of 102 mm². (Courtesy of New World Medical, Rancho Cucamonga CA, USA)

Fig. 4: Aurolab aqueous drainage implant (AADl) is a CE Mark approved, low-cost copy of the BG 101–350 Baerveldt® glaucoma implant (Fig. 2a above). (Courtesy of Aurolab, Madurai, India)



Their results show an efficacy and safety profile that is comparable with published reports of the BGI and Ahmed glaucoma valve implants in children.

Indications and Contraindications

Glaucoma drainage devices are employed in childhood glaucoma when conventional angle surgery (goniotomy or trabeculotomy) has already failed or is believed unlikely to work. At such a point in clinical decision-making, most surgeons choose between a GDD and a trabeculectomy with anti-scarring agents. GDD surgery is also indicated when trabeculectomy is unlikely to work, e.g., in eyes with glaucoma following congenital cataract surgery or when trabeculectomy with anti-scarring agents has failed.

Advantages and Disadvantages

Table 2 broadly summarizes the pros and cons of GDD and trabeculectomy. There are no prospective randomized clinical trials comparing the two procedures in children. The Tube versus Trabeculectomy (TVT) study [14, 15] was a prospective randomized clinical trial comparing the Baerveldt® glaucoma implant to mitomycin C augmented trabeculectomy in adults greater than 18 years of age with prior failed trabeculectomy or prior cataract surgery. After 5 years of follow-up, the GDD group had a higher success rate than the trabeculectomy group with comparable complication rates, visual acuity outcomes, and medication burden. Although not directly applicable to the pediatric age group, GDDs are used most often in the eyes of older children with scarred conjunctiva, so the TVT provides at least some guidance to the surgeon considering a GDD or a trabeculectomy in such eyes.

Table 2: Pros and cons of glaucoma drainage devices compared to trabeculectomy in children.

	Glaucoma drainage device		Trabeculectomy with MMC	
	Pros	Cons	Pros	Cons
Technique	Can be done with cloudy cornea	Violates conjunctiva Hardware in the eye	Can be performed with cloudy cornea No hardware left in the eye	Violates conjunctiva
Outcomes	Effective long-term IOP reduction, even after failed trabeculectomy Most likely to survive future intraocular surgery	Higher long-term IOP compared with trabeculectomy More likely to require supplemental medications Further surgery for complications more likely [73]	Lower long-term IOP Supplemental medications less likely	Poor results in glaucoma following cataract surgery even with MMC Less likely to survive future intraocular surgery
Complications	Lower risk of endophthalmitis	Risk of intra- and postoperative hypotony Risk of tube-related complications: corneal decompensation, cataract, tube erosion, migration, and obstruction Greater risk of postoperative motility disturbance	No tube-related complications	Risk of intra- and postoperative hypotony Lifelong risk of postoperative endophthalmitis if avascular bleb develops, especially if contact lenses are required
Quality of life	Contact lens wear possible (important for aphakic eyes with glaucoma) Post-op care involves fewer manipulations, reducing number of EUAs			Contact lens wear not recommended Post-op care requires frequent visits for close follow-up and possible suture adjustments/5FU injections which in turn might require more frequent EUAs

IOP intraocular pressure, *EUA* examination under anesthesia, *MMC* mitomycin C, *5FU* 5 Fluorouracil

Another consideration in balancing the decision between a trabeculectomy and a GDD is whether or not further surgical interventions are anticipated. The functioning of a well-established trabeculectomy will tend to diminish or even fail after further surgeries such as penetrating keratoplasty or even after uncomplicated cataract removal [16], e.g., in uveitic eyes. In eyes likely to need additional surgery after glaucoma surgery, a GDD is much more likely than trabeculectomy to continue functioning postoperatively. For this and other reasons, we firmly believe that a team approach to complex childhood glaucoma is key to successful outcomes,

especially one that engages cornea, pediatric, and vitreoretinal specialists early on to develop a long-term plan of care that includes the proper sequencing of interventions.

Preoperative Considerations and Preparation

Preoperative examination and planning are essential for successful surgical outcomes. In infants and young children, a thorough examination sufficient to plan surgery may not be feasible in the clinic, and the decision on surgical approach may only be made in the operating room following an examination under anesthesia (EUA).

Important Considerations for GDD

Axial Length Measurement of the axial length is important in the baseline assessment and ongoing monitoring of children with glaucoma. Progressive increases in the axial length of an eye in excess of normal growth may indicate poorly controlled IOP. In the context of planning for a GDD, axial length measurement may influence device selection (see below). In buphthalmic eyes that are adult size or larger, adult GDDs are commonly used.

Conjunctival mobility, which may constrain which quadrant is best for GDD implantation or preclude a trabeculectomy if the choice between procedures has not yet been made. It is often useful to inject balanced salt solution (BSS) into the subconjunctival space with a 30-gauge needle to help delineate episcleral scarring.

Gonioscopy, which will help visualize the presence of iris strands, membranes, or peripheral anterior synechiae (PAS) which might interfere with the insertion of the tube into the AC. If implantation is planned in a quadrant with broad PAS, a surgical peripheral iridectomy can be performed through a small corneal incision in the area of planned tube insertion to avoid having the tube end up under the iris.

Anterior chamber depth and lens status, visualized clinically by slit lamp, under the operating microscope, gonioscopy, or by ultrasound. This is done to determine if tube insertion into the AC can be safely performed both avoiding tube-corneal touch and damage to the crystalline lens. In pseudophakic or aphakic eyes, it may be preferable to place the tube in the ciliary sulcus or pars plana in combination with a pars plana vitrectomy or through a surgical peripheral iridectomy to keep the tube as far away from the corneal endothelium as possible.

Size of the palpebral aperture and motility of the globe are important in providing surgical access to insert a GDD. It may be necessary to perform a lateral canthotomy in some cases of small palpebral aperture to gain sufficient access for surgery. Ocular motility considerations include how to handle the GDD placement when strabismus is present before surgery, especially if the eye to be operated has had prior extraocular muscle surgery. An additional topic, and one which is beyond the scope of this chapter, includes how to handle strabismus induced or worsened by GDD placement.

Scleral Integrity The eyes which have had previous surgical procedures, trauma, or transscleral laser may have areas of scleral thinning which will influence the choice of quadrant used for GDD placement.

Choice of GDD Patch Although many surgeons will use commercially available patches (e.g., Tutoplast® pericardium, dura, or fascia lata) or donor grafts (e.g., sclera or cornea), some surgeons prefer to fashion a long scleral tunnel to cover the tube.

Choice of GDD

The decision of which implant to use in a specific case is based on a number of factors, including the underlying glaucoma diagnosis, level of IOP and ability to control IOP medically, ocular size, orbital anatomy, and finally surgeon preference.

Glaucoma Diagnosis GDDs lower IOP in all forms of childhood glaucoma, and there are no prospective randomized clinical trials comparing the different implants in children on which to base device choice. However, the specific form of disease may influence the choice of implant. In children with the potential for decreased aqueous production, e.g., eyes with uveitis or eyes that have already undergone cyclodestructive procedures, a valved or smaller surface area non-valved implant may be a better choice to avoid hypotony.

IOP Level The level of IOP and the ability to control the IOP with medications postoperatively can influence the choice between a valved or non-valved implant. The adult literature suggests that the non-valved 350 mm² Baerveldt® glaucoma implant may be superior to the Ahmed glaucoma valve in terms of long-term IOP-lowering and medication burden [17]. Hence, if the IOP in a child can be controlled with medications for 6 to 8 weeks while the non-valved implant is temporarily occluded, the surgeon may choose to use a Baerveldt implant in the hope of achieving slightly better long-term IOP control. In contrast, the Ahmed glaucoma valve lowers IOP immediately, which may be of prime importance especially if the child is in pain, has advanced glaucoma, and cannot tolerate medications or if corneal edema is causing amblyopia.

Ocular Size and Orbital Anatomy Often by the time pediatric eyes have already failed one procedure and require GDD surgery, the eyes have grown to adult size or larger. In such cases, adult-sized implants may usually be implanted without too much difficulty. As noted earlier, IOP-lowering is roughly proportional to plate size, so it is generally in the long-term interest of the child to implant an adult implant whenever possible. In contrast, when GDDs are used as primary surgery or in very young infants with small eyes (e.g., those with true microphthalmia), the physical size of adult implants comes into play.

GDDs are best implanted with the anterior edge of the plate at least 8 mm posterior to the surgical limbus. When an adult-sized GDD is placed in this position, the posterior edge of the implant plate may impinge on the optic nerve in young infants. Margeta and colleagues [18] measured the limbus to optic nerve distance in the superior temporal quadrant in 15 pediatric autopsy eyes. Figure 5 demonstrates that in a pediatric eye with axial length of 19 mm, an adult-sized Ahmed Model FP7 glaucoma valve, placed in the inferior nasal quadrant with the anterior edge

sutured 7 mm from the limbus, overlaps the optic nerve to a significant degree. The Freedman-Margeta formula (<http://people.duke.edu/~freed003/GDDCalculator/>) offers a way to determine limbus to optic nerve distance in pediatric and small eyes in order to reduce the risk of optic nerve impingement by the posterior edge of the GDD plate. The Ahmed glaucoma valve is available in pediatric sizing (FP8 and S3 versions) as is the Molteno™ implant (P1 version); the posterior edge of the 350 mm² BGI and the AADI can be easily trimmed with a heavy surgical scissors to create a cutout to accommodate the optic nerve. The 250 mm² version of the BGI is designed with a posterior notch to avoid overriding the optic nerve.

Operation

Intraoperative Preparation

The surgical field should be cleaned with sterile iodine or chlorhexidine-based preparation fluid, the area dried, and a surgical drape placed over the eye. Self-adhesive ophthalmic drapes with a transparent window and a pocket to collect irrigation fluid are desirable. This may be applied with the lids open and the lashes everted so that when the drape is cut open to apply a lid speculum, the lashes are retained underneath the sticky drape without straying into the surgical field.




Fig. 5: Photograph of a pediatric autopsy eye (axial length 19 mm), showing an Ahmed Model FP7 glaucoma drainage device sutured in the superonasal quadrant. The anterior edge of the plate is located 7 mm from the limbus; note the extensive overlap of the posterior edge of the Ahmed device plate and the optic nerve. (Courtesy of Milica Margeta, MD, PhD and Sharon Freedman MD)

With the lids held open by an ophthalmic speculum, a drop of 1:10,000 adrenalin or other topical ocular sympathomimetic drug may be instilled to promote vasoconstriction of the conjunctiva and episclera and minimize tissue bleeding.

The usual position for a GDD is in the superior temporal quadrant. The surgeon will generally be positioned superiorly or in the superior temporal position approximately 45° from the vertical; if the microscope permits, the assistant can be positioned superiorly.

Surgical Technique

A recommended set of instruments and suture materials for GDD surgery are listed in Table 3. Implantation of GDDs in pediatric patients requires special attention to the size of the eye and orbit, the thickness of the sclera, and the positioning of the tube in an eye that will continue to grow.

Traction Suture A corneal traction suture is placed in alignment with the intended quadrant to rotate the eye inferior-nasally to provide the best surgical exposure. This may be placed through partial-thickness cornea in the mid-periphery of the same quadrant or at the limbus on either or both side(s) of the planned entry site. The conjunctiva and surgical exposure are then evaluated for scarring, and sufficient room to place a GDD is confirmed.

Conjunctival Incision Most surgeons perform fornix-based conjunctival flaps (e.g., the incision is made at the limbus) for GDD implantation, but a limbus-based conjunctival flap (where the incision is placed approximately 6–8 mm posterior to the limbus) has several advantages in pediatric eyes. It facilitates placement of the sutures securing the plate to the sclera in the very tight pediatric orbit, and the incision can be closed confidently in a watertight manner that will not unravel if the child rubs the eye vigorously. And importantly in children with aphakia, contact lens use can often be resumed within days of surgery. In contrast, incisions at the limbus are more

Table 3: Recommended instruments and suture materials for glaucoma drainage devices implant surgery.

Instruments and knives		Sutures and consumables	Device related
Eye speculum	Tenotomy scissors		GDD of choice
Caliper	Vannas scissors – straight, curved	7-0 Vicryl® or Mersilk for corneal traction suture	BSS on a 27- or 30-gauge cannula
Muscle hook	Mini-crescent blade	8-0 nylon on a spatulated needle	23- or 25-gauge needle
Conjunctival forceps	MVR blade/supersharp	8-0 or 9-0 Vicryl® for conjunctival closure	Patch graft material
Tying forceps	Conjunctival clamp	Viscoelastic	
Colibri forceps	Needle holder	Anterior chamber infusion	

GDD glaucoma drainage device, BSS balanced salt solution, MVR micro vitreoretinal

uncomfortable for children, and contact lenses cannot be resumed for several weeks in most cases. In a retrospective comparison of limbal-based to fornix-based incisions for GDDs in adults, Suhr *et al.* found no difference in IOP outcomes [19].

Another important consideration for incision type arises in children with aniridia. In these patients, limbal stem cell deficiency arises that leads to corneal conjunctivalization and opacity later in life. A limbal incision, cautery, and mitomycin C application are likely to be detrimental to the limited reserve of stem cells in these patients. For patients with aniridia, a limbal-based (limbus sparing) conjunctival technique is recommended, and the use of MMC is avoided.

Device Preparation and Placement Once the conjunctival incision is made, dissection and elevation of Tenon capsule from the episclera are carried out, and the adjacent rectus muscles are identified with a muscle hook. Tenotomy scissors are used to clear all adhesions and check ligaments posterior to the incision to clear the potential space for the implant and to facilitate the easy implantation of the selected device. Alternatively, blunt dissection of the correct plane may be started with scissors and completed with two squint hooks inserted back-to-back in this pocket and pulled gently apart, as demonstrated in the Video 1.

Before implanting an AGV, it is imperative that the surgeon “prime” the device with BSS. The silicone leaflets of the valve device stick together during manufacture, and if they are not primed with BSS, the device will fail. A 27- or 30-gauge cannula on a syringe filled with BSS is inserted into the tip of the silicone tube. BSS is gently injected into the tube, and flow is observed through the valve leaflets under the microscope [20]. Once this is done, the device is “primed,” and implantation in the selected quadrant may proceed.

A muscle hook may be used to engage the superior rectus muscle; the AGV device can be grasped gently with smooth forceps with care taken not to crush the portion of the device housing the valve mechanism. With forward traction on the muscle hook, the device is placed between the two rectus muscles and pushed posteriorly. When adequate preparation of the quadrant and clearance of adhesions or check ligaments has been done, the device will achieve a resting position with the anterior suture holes approximately 8 mm posterior to the limbus.

In the case of a BGI or AADI, the superior rectus muscle is engaged with a muscle hook and the implant plate grasped with large non-toothed forceps (e.g., Nugent or Moorfields forceps) and the appropriate wing of the implant placed under the muscle. A second non-toothed forceps is then used to grasp the opposite wing of the implant, and the muscle hook removed from under the superior rectus and repositioned under the lateral rectus muscle. The plates of these devices are quite flexible, so by grasping and bending the plate, the temporal wing can be easily placed under the lateral rectus muscle. The implant is then gently pulled forward to verify that it has achieved a good position between and under the two rectus muscles. It is not pulled tightly up under the muscle but rather should rest gently behind the muscle insertions with the suture holes positioned some 8–10 mm posterior to the limbus.

Because the BGI and AADI devices are not valved, the tube portion of the device must be temporarily occluded. In adults, this can be done with absorbable sutures, sutures that can be

lasered or with a rip cord that is removed later at the slit lamp in older children and adults and in the operating room in young children. The absorbable suture technique is appropriate in young children and is described here along with the optional modification of an intraluminal stent to reduce the chance of hypotony. A suture of 6-0 or 7-0 polyglactin suture is tied around the silicone tube a few mm anterior to the plate. A 27- or 30-gauge cannula on a syringe filled with BSS is inserted into the tip of the silicone tube, and complete occlusion of the tube is confirmed. Ligation of the implant tube can be performed based on the surgeon's preference either on the back table of the operating room before implantation or under the operating microscope after the device is in place or sutured to the sclera. Any flow through the tube must be avoided in children as a flat chamber is likely to result that will necessitate an early return to the operating room.

In addition to the extraluminal absorbable tie, an intraluminal stent may be used to partially occlude the lumen. A nonabsorbable suture thread (e.g., 3-0 Prolene® or 3-0 Supramid®) is used with one end fed into the GDD tube at the plate and the distal end tracked beneath the conjunctiva, often into the inferior fornix. Following the absorption of the extraluminal tie at 6–8 weeks, the presence of this intraluminal stent mitigates the risk of hypotony. If, however, the IOP remains poorly controlled after the absorption of the Vicryl tie, the stent may be subsequently removed by making a small incision over its distal end in the lower fornix and the whole thread pulled out remotely from the device. The conjunctival incision is closed with a pre-placed Vicryl purse string suture.

Plate Suturing The next step in the procedure is to affix the plate to the sclera. A suture on a spatulated needle is used to make a deep partial-thickness pass just in front of the plate taking care not to penetrate the sclera, which can be quite thin in a buphthalmic eye. The suture is then passed through the fixation hole of the implant and tied down tightly to minimize plate movement. When possible, the knot should be rotated into the fixation holes to avoid the short lengths of suture eroding through to conjunctiva resulting in irritation or serious infection. Molteno described the use of 7-0 silk to secure the plate of his device to the sclera [7], and others advocate the use of non-absorbable sutures, such as polyester (Mersilene®) or polypropylene (Prolene®). Current implants are designed with holes in the plate that allow tissue “rivets” to form between the sclera, through the hole, and to the capsule above. Once these tissue rivets are formed during the first few months of healing, the implant will not move.

Silk can cause significant local inflammation, and nonabsorbable sutures may cause the overlying conjunctiva to break down or erode, sometimes many years later. We recommend 8-0 Nylon to secure the implant in place on the sclera. Nylon has sufficient tensile strength to tie down the implant tightly; the material begins to degrade only after a year or so has passed, long after the tissue rivets have secured the implant in place. After several years, the nylon disintegrates, eliminating the risk of late conjunctival erosion.

Tube Implantation Insertion of the tube into the AC is the most challenging aspect of pediatric GDD surgery. The surgeon must account for an AC that may be shallow but also plan for the long-term growth of the eye.


An AC paracentesis is performed (e.g., using an MVR blade); if the child was dilated for an EUA or photography, a quick-acting miotic is first injected into the eye to constrict the pupil. A viscoelastic substance is injected, or an AC infusion inserted, to avoid intraoperative hypotony. The scleral surface anterior to the plate is cleared of adhesions, and gentle cautery is applied, if required, to dry the surface. When a limbus-based conjunctival flap has been created, the assistant can use a surgical conjunctival clamp (Khaw conjunctival clamp [Duckworth & Kent Ltd., Baldock, Hertfordshire, UK], Khaw/Shah 4 mm conjunctival clamp [Duckworth & Kent], or Lama cross-action 5 mm conjunctival forceps [Moria Inc., Doylestown PA, USA]) to grasp the flap and provide good surgical exposure (Fig. 6). The tube entry in children is usually created in an oblique direction so that the tube can be left long enough to accommodate growth without extending into the pupillary aperture. The tube is laid down on to the intended path of implantation and is trimmed to an appropriate length creating an anteriorly oriented beveled tip. Before entering the eye with a needle to create a pathway for the tube, the AC is reassessed and the previously placed side-port incision used to deepen the chamber with viscoelastic as necessary. This side-port incision should be oriented in such a way that if the tube is misdirected in the eye, a Sinskey hook or iris spatula can be used to redirect the tube into the correct position. If the implant is positioned in such a way that the tube will enter the eye in an area of broad PAS or other obstructions, a surgical peripheral iridectomy can be created through a small corneal incision just inside the limbus. In this manner, the tube can be inserted more posteriorly and then rest in front of the iris but well back from the cornea. Any such corneal incision must be closed with a 10-0 suture of Nylon or Vicryl® as it will leak in a pediatric eye unless sutured.

In adults, a 23-gauge needle is often used to create the tube entry site; in children, the sclera is sufficiently flexible that a 25-gauge needle can be used and the tube can be inserted without too much difficulty. The use of a narrower gauge needle to fashion the tunnel also reduces the risk of leakage of aqueous around the tube and hypotony. Moving the tube entry site several millimeters back from the limbus avoiding a corneal track is important to avoid late erosions, but doing so can make it challenging to get the angle just right to avoid an anteriorly vaulted tube that touches the corneal endothelium. The beveled tip of the tube is then advanced into the needle tract and pushed forward with fine forceps. Alternatively, the tube may be inserted with the assistance of a fine blunt-tipped cannula by engaging the tip firmly onto the bevel of the trimmed tube and passing the cannula gently through the scleral tunnel taking the tube with it (Video 2). The surgeon should watch for the tube to enter the AC periphery where expected; if it does not, the tube may have migrated under the iris, in which case another pass can be tried or a surgical iridectomy created as noted above.

Once the tube has been inserted into the eye, the external portion should be secured to the sclera with a nonabsorbable suture (e.g., 9-0 Nylon) which helps to stabilize the tube. This both reduces the risk of migration out of the eye and also reduces outward bowing of the tube which may increase the susceptibility to erosion through the conjunctiva.

The tube must be covered to prevent its erosion through the overlying conjunctiva over time. The tube may be covered either with autologous tissue or with donor sclera or cornea obtained

Fig. 6: Placement of an Ahmed glaucoma valve in the inferior nasal quadrant through a limbal-based conjunctival incision. The adult-sized plate (Model FP7) has already been sewn in place approximately 10 mm posterior to the limbus in this buphthalmic eye with a 25 mm axial length. Lama cross-action conjunctival forceps provide excellent exposure. (Courtesy of James D. Brandt, MD)



from an eye bank or dehydrated and preserved donor dura mater or pericardium [21]. This graft material is usually sutured into place with one or two sutures of fine (8-0 or 9-0) polyglactin; a permanent suture is not needed as graft materials rapidly incorporate into the surrounding Tenon capsule or conjunctiva.

Although autologous tissue may be obtained from fascia lata or temporalis fascia, many glaucoma surgeons now advocate using the patient's own sclera to support and cover the tube. This can be challenging in the thin sclera of a buphthalmic eye but can be done in a number of ways, the simplest of which is by creating a scleral flap. Alternatively, a long tunnel in the patient's native sclera may be created using a bent needle starting some 5 mm posterior to the limbus. Another method employs a small mini-crescent blade (1.25 mm in width) (Video 3) that can be used to tunnel in the sclera up to about 2 mm posterior to the limbus, then completing the entry into the eye with a 25-gauge needle.

Once the tube has been inserted, any viscoelastic remaining in the eye is expressed through the side-port incision or washed out with irrigation. While some viscoelastic may be left in the eye safely when a valved implant is placed, it should be aggressively removed from the eye when a non-valved implant is used, as any retained viscoelastic will cause a dramatic rise in IOP. The AC is then refilled to a physiologic level with BSS to determine where the tube will end up in relation to the iris or cornea. If the tube is vaulted too far forward and risks touching the endothelium with eye rubbing, it is far better to revise the tube position and/or length at the initial surgery than returning to the operating room months or years later after endothelial loss has occurred.

Incision Closure Tenon layer and conjunctiva are securely sutured to ensure adequate coverage of the plate, tube, and patch graft/scleral flap, preferably with absorbable sutures to avoid returning to the operating room and further anesthetic exposure to deal with irritating sutures. A

sub-Tenon injection of long-acting local anesthetic performed during closure can help with early postoperative pain relief.

The sclera is often thin in pediatric eyes and the tissues less rigid than adult eyes. It is therefore frequently necessary to suture the paracentesis used for the AC infusion or viscoelastic in order to avoid postoperative leaks; 10-0 monofilament Vicryl® is used when available for the same reason described above.

At the end of the operation, the eye should be inspected to ensure that the implant plate, patch graft, and intraocular portion of the tube are in a good position, that the AC is well formed, and that a clear red reflex can be seen. Fluorescein drops or strips can be used to inspect the conjunctiva and cornea for leaks, and instillation of a cycloplegic such as atropine will assist in deepening the AC. A subconjunctival injection of corticosteroid and antibiotic is commonly performed at the end of the procedure.

Modifications to Standard Technique

Some modifications to the technique of GDD surgery have already been mentioned and relate to surgeon preference and experience; however, modifications to the standard technique may be dictated by scarring and tissue distortion from previous surgery and trauma or by the underlying diagnosis.

Conjunctival Scarring Although superotemporal placement of the drainage device is often preferred, circumstances may dictate that a superonasal or inferior placement of the tube is required. Examples include eyes where previous glaucoma surgery has taken place in the superior temporal quadrant or where PAS preclude entry of the tube into the AC at that site.

The use of explants for the repair of retinal detachments is infrequent now; however, if a GDD is required in this circumstance, placement of the plate may need to be behind or even on top of the explant. Before placing a GDD in such eyes, it is essential to ensure that adequate and sufficiently mobile Tenon capsule and conjunctiva are available to cover the hardware before placing such a device.

Prior Strabismus Surgery If a rectus muscle has been resected in the quadrant planned for the GDD placement, one needs to prepare for additional scarring around the muscle insertion, but usually careful technique will allow the GDD surgery to proceed without major modification. By contrast, a previous rectus muscle recession (e.g., lateral rectus for a planned GDD in the superior temporal quadrant) may call for a modified GDD procedure, especially in the case of a planned Baerveldt GDD. Basically, for a Baerveldt to be placed in a quadrant where an adjacent rectus recession has previously occurred, the surgeon must identify the insertion of the recessed muscle and then may either trim the front of the respective wing to allow that wing to be placed behind the recessed rectus muscle (personal communication, SFF) or may trim the back of the respective wing, such that the wing is entirely in front of the rectus muscle. This latter technique may lead to making the anterior portion of the bleb in front of the muscle much more visible, which is often cosmetically problematic, and is therefore not recommended.

It may be preferable in this case to place the plate in the superonasal quadrant, that is, in the quadrant with the resected rather than the recessed horizontal muscle. In the case of a preexisting strabismus, such as an exotropia, the surgeon may elect to recess the lateral rectus muscle concurrent with the GDD placement (especially in the case of a planned Baerveldt implant), because the muscle will be much harder to access after the GDD surgery. As described above, it is recommended that the anterior portion of the, respectively, Baerveldt wing be trimmed to allow the recessed rectus to remain anterior to the Baerveldt wing.

Glaucoma Following Cataract Surgery (GFCS) GDDs are frequently the preferred primary procedure in the management of glaucoma following cataract surgery, particularly in aphakic eyes where contact lens is planned. In this circumstance, a trabeculectomy is contraindicated due to increased risk of bleb-related endophthalmitis.

A success rate for controlling the IOP following cataract surgery has been reported of up to 90% at 1 year [22], and in addition, GDDs allow children to more easily wear contact lens refractive correction which assists with management of amblyopia. Tube insertion may be performed in the sulcus or the pars plana to avoid complications of corneal tube touch [23]. Doing so avoids leaving hardware at or near the limbus where aphakic contact lenses can lead to late-onset conjunctival breakdown over the tube; furthermore, pars plana insertion of the tube protects the corneal endothelium from tube-corneal touch. However, eyes which have undergone cataract surgery may be particularly susceptible to occlusion of the tube tip by capsular remnants, “Elschnig pearls” of residual cortical material, or vitreous. To mitigate this risk, it is essential to consider performing excision of lens pearls, and/or further vitrectomy if the eye is aphakic, and the tube should be positioned away from the iris and capsule.

Vitreous incarceration into the tube can happen shortly after surgery or many years later; in a retrospective review of Baerveldt® implants placed through the pars plana, Vinod *et al.* [9] reported vitreous tube obstruction in 19% of their series, occurring 3–112 months after implantation.

Any mobile vitreous will eventually find its way to the tube tip and occlude it. It is absolutely necessary to perform a meticulous pars plana vitrectomy prior to tube insertion in order to prevent this late complication. If corneal clarity prevents a good view, a surgical endoscope can be used to perform the vitrectomy [24]. The anterior core vitrectomy routinely performed at the time of pediatric lensectomy is insufficient; even in an aphakic eye that was vitrectomized at the time of cataract extraction, the vitreous base must be shaved down aggressively under direct visualization and an attempt made to cause a posterior vitreous detachment to elevate and remove the posterior hyaloid face. In young children in particular, the posterior hyaloid face is difficult to detach during vitrectomy, and it is this posterior shell of vitreous and hyaloid that can detach years later.

Care should be taken to ensure that the tube is trimmed to a length which allows direct visualization of the tip, particularly when it is inserted through the pars plana as this assists in diagnosing or excluding occlusion as a cause of GDD failure.

Sturge-Weber Syndrome Patients with Sturge-Weber syndrome may have associated choroidal hemangioma, and it is important to diagnose this prior to surgical intervention. Precipitous reduction in IOP or hypotony may result in a suprachoroidal hemorrhage, which can be sight

threatening. Choroidal effusions are more common and may even occur undetected in the early postoperative period (Fig. 7). It is therefore essential to take measures to avoid both intraoperative and postoperative hypotony. The use of an AC infusion is helpful to maintain the IOP while the tube tunnel is fashioned and the tube inserted. Care should be taken to ensure that the tube tunnel is tight and that there is no peri-tube leak following insertion. The use of extraluminal tube restricting ligatures and intraluminal stents in non-valved devices is essential; great caution is recommended if a valved device is chosen and implanted without ligating the tubing, as choroidal effusions may be severe in the early postoperative period. Choroidal effusions may occur at higher-than-expected IOP in the presence of choroidal hemangioma, and it is advisable to omit glaucoma medications until review on the first postoperative day confirms the IOP. B-scan ultrasound examination is useful in monitoring for choroidal effusion.

Uveitis Surgical intervention in an eye with uveitis risks exacerbating inflammation which, in turn, may threaten the success of surgery. It is therefore desirable to optimize both systemic and topical immunosuppression before performing glaucoma surgery, and this may require collaboration with the pediatric rheumatologist. Complications of GDD surgery particularly related to poor control of intraocular inflammation include occlusion of the tube tip with fibrin, ciliary body shutdown, and hypotony. Hypotony is a risk in these eyes even in the absence of active inflammation as a consequence of poor ciliary function, and the risk is particularly high if the eye has previously undergone cyclodestructive procedures which are advised against in these eyes. Care should therefore be taken when performing GDD surgery to avoid over-drainage. For this reason, valved devices may be useful in these eyes, and if a non-valved device is preferred, the use of a restricting ligature and intraluminal stent is advisable. The choice of a small plate size in either a valved or non-valved device is also helpful.

Aniridia Aniridic eyes have limbal stem cell deficiency that leads to corneal conjunctivalization and opacity later in life. As previously mentioned, a limbal-based (limbus sparing) conjunctival technique is recommended, and the use of MMC is avoided in children with aniridia.

In addition, careful positioning of the tube in the AC is necessary to avoid it touching the lens, which is unprotected by the iris, as this results in cataract formation (Fig. 8). Tubes are commonly inserted into the eye in a radial or slightly oblique angle; however, a more aggressively tangential approach is used in cases of aniridia where it is desirable to avoid having the tube lying across the unprotected lens; a similar approach is sometimes taken in the setting of a corneal graft when it is desirable to have the tube lie beneath the host cornea rather than under the graft (Video 4).

The Role of Antimetabolites in GDD Surgery

Pediatric eyes frequently mount an exuberant healing response to the implantation of a foreign body such as a GDD; for this reason, some pediatric glaucoma surgeons advocate the use of antimetabolites at the time of surgery. Costa and colleagues performed a masked, randomized prospective clinical trial comparing the intraoperative use of MMC (0.5 mg/ml \times 5 min] to BSS in adults older than 18 years of age undergoing AGV implantation (three of their subjects carried the

Fig. 7: Coronal reconstruction of an MRI performed on an infant with Sturge-Weber syndrome to evaluate central nervous system involvement in the disease. The scan was acquired 1 week after implantation of an Ahmed glaucoma valve in the superior temporal quadrant of the left eye. Note the lucent area representing the silicone implant, along with the annular choroidal effusion. The effusion had resolved by the next clinic visit and was never observed clinically. (Courtesy of James D. Brandt, MD)



diagnosis of “congenital glaucoma,” but they were adults at the time of the study) [25]. They found no difference in short-term success at 1 year.

The role of antimetabolites in GDD success has yet to be established in the pediatric population. There are no prospective, randomized clinical trials comparing the intraoperative use of mitomycin C (MMC) in pediatric implants. Cui and colleagues performed a retrospective review of adjuvant treatment with antifibrotic agents during and after AGV implantation and reported decreased frequency of the hypertensive phase commonly observed with this device and improved surgical outcomes at 1 year [26]. A retrospective, nonrandomized study of AGV both with and without mitomycin C (MMC) in aphakic glaucoma showed no difference in IOP control between groups [27]. A larger retrospective study demonstrated worse outcomes after 2 years of follow-up in eyes receiving AGV plus MMC [28], though this may be due to differences in underlying diagnosis and previous number of surgical interventions between groups. A prospective randomized study looking at AGVs augmented with either Bevacizumab, MMC, or no MMC found higher success rate groups receiving both Bevacizumab and MMC at 1 year [29].

The bottom line is that the long-term safety and efficacy of the adjunctive use of antimetabolites in pediatric GDD surgery are not known. A surgical registry approach to capturing data on pediatric GDD surgery over many years may be the best way to determine the risk/benefit balance of antimetabolites in this population for whom long-term outcomes are so important.

Postoperative Management

Postoperative medication includes topical broad-spectrum antibiotic (e.g., chloramphenicol or fourth-generation fluoroquinolone), topical steroid (e.g., prednisolone acetate 1% or dexamethasone 0.1%), and often a topical cycloplegic (e.g., atropine 1% or cyclopentolate 1%). When a non-valved device has been implanted using an extraluminal tie and/or intraluminal stent, it may also be necessary to continue topical glaucoma medication until the extraluminal suture is absorbed and the tube opens. For those children with a valved tube, the device will function immediately, and often all the regular glaucoma medications can be stopped.

Pain relief is usually adequately managed with acetaminophen appropriately dosed by weight, with the addition of a systemic nonsteroidal anti-inflammatory drug if required.

Children are examined on the first postoperative day, and assessment should be directed to identify potential complications of surgery as detailed below. It is usually impossible to formally measure IOP in a young child on the first postoperative day, but if necessary the IOP may be estimated by gentle digital palpation over the closed lid. External examination will reveal any purulent discharge or bleeding, and ocular examination should aim to confirm the presence of a formed AC and clear red reflex. If necessary, a B-scan ultrasound examination can assist in assessment.

At 1 week after surgery, a more detailed exam is usually possible. In the presence of nonabsorbable sutures on the conjunctiva or cornea, antibiotic drops should be continued until they are removed. However, when absorbable sutures have been used for closure, antibiotics can be stopped within the first week or two postoperatively. The key issues during the first month or so after GDD surgery are infection surveillance, AC status, IOP, and tube positioning. If the IOP is very low, and the AC is very shallow or flat, reformation with viscoelastic in the operating room is urgently necessary to avoid corneal failure or cataract. B-scan ultrasound can help determine if choroidal effusions are present, and this can be done even in a crying infant in the clinic setting.

Topical cycloplegic, if used, may be stopped shortly after surgery if there is no hypotony and the AC remains deep. However, this medication may be temporarily reinstated around the time of opening of the extraluminal tie if there is a significant risk of hypotony. Topical steroid therapy should be tapered postoperatively according to the presence and grade of AC activity and external conjunctival hyperemia, usually over 1–2 months.

Management of valved versus non-valved GDDs diverges significantly in the postoperative period. In the case of a valved implant, preoperative glaucoma medications are usually discontinued to prevent hypotony. For those children who have had a non-valved device inserted utilizing an absorbable suture extraluminal tie, a critical time for review is around 6–7 weeks postoperatively when the tie usually spontaneously releases. In order to avoid hypotony at this time, it may be advisable to reduce or stop glaucoma medication a few days in advance. By this point, a fibrous capsule will have formed around the plate; this capsule offers resistance to outflow and thus avoids hypotony.




Fig. 8: (a, b) Bilateral glaucoma drainage devices placed at age 8 in a boy with glaucoma associated with aniridia . There is no tube-lens touch, but over the last 5 years, the lenses slowly dislocated upward, as shown, and developed early posterior subcapsular cataract with visual acuity in the 20/50 range bilaterally (patient does not have foveal agenesis). (a, b Courtesy of James D. Brandt, MD). (c) Tube of a Baerveldt glaucoma drainage device inserted at a tangent so that it lies near the equator of the lens (the thinnest portion of the lens) to avoid the tube touching the lens. (d) Tube of a Baerveldt glaucoma drainage device in an aniridic eye. The tube is inserted in a radial direction with the tip of the tube approaching the anterior pole of the lens (the thickest portion of the lens) resulting in the tube touching the lens and causing a localized opacity. (c, d Courtesy of Cecilia Fenerty, MD, FRCOphth)

Further, EUA may be required to fully assess tube function and IOP control or for the removal of nonabsorbable sutures or the intraluminal stent. This should be planned at or beyond 6 weeks following surgery at which time any absorbable extraluminal tie will have spontaneously opened.

The “hypertensive phase” following GDD implantation is a widely recognized phenomenon, particularly with the Ahmed glaucoma valve [30], and is associated with high postoperative IOPs [31]. Approximately 4–6 weeks after implantation, the capsule forming around the AGV tends to thicken and offer more resistance to aqueous outflow. It is important to monitor for the onset of the hypertensive phase and if necessary reinstitute glaucoma medications at the earliest indication of a rise in IOP [32]. In a prospective study in adults, Pakravan and colleagues demonstrated that early aqueous suppression resulted in improved long-term IOP reduction and reduced the frequency of the hypertensive phase [33].

Complications

Although GDDs offer some benefits over other surgical procedures, they also carry the risk of significant complications. Complications which are particularly common or are unique to GDDs are described below.

Hypotony

Hypotony may be a serious and sight-threatening complication which may occur as an early, medium-term, or late complication of GDD surgery. It is often associated with a shallow or flat AC, maculopathy, choroidal effusion, serous retinal detachment, or suprachoroidal hemorrhage. Postoperative review should place an emphasis on assessing for the presence of hypotony and associated complications so that treatment can be initiated early. Further complications such as PAS, cataract, or phthisis may ensue if hypotony is not appropriately managed.

Buphthalmic eyes, which are large with little scleral rigidity, are particularly at risk of the complications of hypotony. Perioperatively, hypotony is avoided by the use of viscoelastic agents or AC infusion to maintain the AC. The use of appropriate-sized devices, small gauge needle entry, valved devices, and suture restriction of non-valved devices as described above reduces the risk of postoperative hypotony. In circumstances when hypotony occurs despite the above measures, assessment needs to be made as to whether this is due to over-drainage or under production of aqueous (ciliary body shutdown).

Over-drainage in the early postoperative period may occur due to:

- Leakage around the tube at the site of the scleral tunnel
- Failure of the valve mechanism in a valved device
- Lack of adequate restriction of a non-valved device
- Drainage via a different path, e.g., preexisting trabeculectomy exposed during GDD surgery, iatrogenic cyclodialysis cleft

Over-drainage may occur as a medium-term or late complication when a restricting ligature is released or an intraluminal stent removed in a non-valved device. Tube exposure (described below) may also result in leakage and over-drainage as a late complication. Management of clinically significant hypotony due to over-drainage will require surgical intervention to identify and remediate the underlying cause. The use of an AC infusion assists in identifying areas of aqueous leakage around the tube or through the tube when extraluminal restriction is not adequate. Suturing the tube tunnel on either side of the tube may stop leakage from this site; however, sometimes it is also helpful to use a small amount of Tenon capsule to plug the leak. Tubes which are draining because of inadequate restriction will require an additional tighter tie to be applied. In the extreme situation where these measures do not stop leakage, the tube is removed from the tunnel, which should be sutured closed. The surgeon should then decide whether to fashion a fresh tunnel or simply tuck the tube out of the way for later reinsertion, thus converting the surgery to the “two-stage” approach described at the beginning of the chapter.

Ciliary body shutdown as a primary cause of postoperative hypotony is most commonly encountered in eyes with glaucoma secondary to uveitis or in eyes that have previously undergone multiple ciliary ablations. Eyes which suffer a period of hypotony may additionally suffer ciliary body shutdown and aqueous hyposecretion as a consequence of ciliary body detachment with choroidal effusions. Primary ciliary body shutdown may require additional restriction or stenting of the tube to limit drainage while awaiting restoration of ciliary body function. In addition to aggressive management of any underlying inflammation, consideration should be given to artificially elevating the IOP by use of viscoelastic, BSS, gas (e.g., filtered air or 20% SF₆), or a combination of these into the AC.

Tube Occlusion

Tube occlusion may occur early or late in the postoperative period, and for this reason, it is important in siting the tube and trimming its length to ensure that the tip is directly visible. In eyes having undergone cataract surgery, occlusion may be related to capsular remnants, lens pearls, or vitreous as described elsewhere in this chapter. Fibrin may also occlude the tube from intraocular inflammation postoperatively or blood in the presence of a hyphema.

Rates of tube obstruction in different pediatric glaucomas with different drainage devices range from 6% to 20% [34-44]. Surgical removal of the obstruction is often required. The options depend on the underlying cause but may involve a combination of tube flushing, AC washout, vitrectomy, iridectomy, or removal of the valve mechanism in an AGV.

Patients with a late-onset vitreous incarceration present with sudden, marked IOP elevation after months or years of good IOP control. B-scan ultrasound reveals no bleb over the plate, indicating blockage of the tube. If the patient can cooperate, vitreous incarceration can be seen in the tube tip at the slit lamp or with a gonioscopy prism in a dilated eye. Vinod and colleagues [23] recommend a surgical approach in such patients. It is not sufficient to simply perform a vitrectomy; these tubes are usually blocked with a plug of condensed vitreous that must be removed with end-grasping retinal forceps (Fig. 9); if only a simple vitrectomy is performed, this now amputated plug will be free to travel up the tube and cause permanent failure. Once the vitreous plug and remaining mobile vitreous are cleared from the tube, full function of the GDD is usually restored, and IOP returns to pre-occlusion levels; B-scan ultrasound will reveal the presence of a filtering bleb over the equatorial plate, confirming flow through the system.

Tube Touch

Corneal touch and endothelial damage occurs when the tube is sited anteriorly in the AC and particularly if the intracameral portion of the tube is long. *Corneal opacification* occurs at the site of tube touch with endothelial damage resulting in *corneal edema* and *decompensation*. The tunnel for the tube should be constructed so that the tube enters the AC in front of and parallel to the iris. If the intracameral portion of the tube is too long, it may be observed at the slit lamp to sweep from side to side or forward and back when the patient blinks or when touching the eyelid on

examination. In a young child, tube touch may be intermittent with eye rubbing, and a focal area of corneal edema near the tube tip seen at EUA may be the only clue that this is happening and may require shortening or repositioning of the tube.

Iris touch may occur if the tube is sited too far posteriorly in the AC. This may result in *chafing of the iris* with localized atrophy or *chronic uveitis*. This may also be associated with *corectopia*, particularly if the iris root is involved; corectopia on this basis is particularly common in eyes with Sturge-Weber syndrome (Fig. 10).

Lens touch results in cataract and may be a consequence of a tube which is too long, sited too far posteriorly, or in a radial rather than tangential direction.

The treatment of tube touch complications is ultimately surgical and is carried out by shortening and/or resiting the tube. In some cases of anterior segment tube-related complications, it is may be necessary to reposition the tube posteriorly through the pars plana [45].

Erosion

Erosion of the GDD through the conjunctiva (Fig. 11) may result in infection (*endophthalmitis*), *leak*, or *hypotony*. Securing the plate and the tube with sutures as described above ensures the device does not sit raised over the underlying scleral plane with the overlying conjunctiva stretched over the device surface. The use of a patch graft cushions the conjunctiva from the ridge of the tube and the anterior plate and further reduces the risk of erosion. However, if the conjunctiva is under tension when replaced to cover the GDD (e.g., as a consequence of scarring from previous surgery or trauma), it is more likely to erode over the tube or plate.

Migration

Migration of the GDD may occur if the plate and tube are not securely sutured to the globe or the “wings” of a Baerveldt implant are placed above rather than behind the muscle insertions. As a consequence, the plate may end up advancing toward the limbus leading to “touch complications” or retracting toward the equator resulting in tube retraction out of the AC. With the device plate well secured, it is still possible for the tube to migrate out of the AC if it is not sutured securely to the sclera or with ocular growth (Fig. 12).

Changes in Intracameral Tube Length

Intracameral tube length may change with the IOP postoperatively. With a reduction in IOP, the dimensions of a child’s eye may change with a reduction of the corneal diameter and the axial length. As a consequence, the intraocular portion of the tube may lengthen, and with that more “tube touch” complications are likely. Conversely, with elevated IOP following surgery, the corneal diameter and the axial length may increase, and the intraocular portion of the tube may retract from the anterior segment.




Fig. 9: Technique of pars plana vitrectomy to remove a vitreous plug occluding a tube as described by Vinod and colleagues. Note that a simple vitrectomy is insufficient – end-grasping forceps must be used to remove the condensed vitreous plug or the plug will be free to travel up the tube and cause permanent failure. (From Vinod *et al.* [30]. Illustration by Jill K. Gregory, CMI. Reprinted with permission from ©Mount Sinai Health System, New York NY, USA)

Ocular Motility Disturbances

Ocular motility disturbances may arise following GDD implantation, particularly when an eye has undergone prior strabismus surgery. Strabismus following GDD surgery should be managed by a surgeon familiar with both muscle surgery and pediatric GDD surgery, as these cases are very complex.

Outcomes

The World Glaucoma Association convened a Consensus Meeting on Childhood Glaucoma at its biennial global congress in 2013; the resulting monograph reported the results of a worldwide surgical consensus survey of glaucoma specialists and pediatric ophthalmologists with an interest




Fig. 10: Tube-related corectopia . Teenager with chronic uveitic glaucoma who underwent placement of an Ahmed Glaucoma Valve about 5 years earlier combined with phacoemulsification and injection of an Ozurdex[™] dexamethasone implant (Allergan, Dublin, Ireland) who returns with maintained IOP control and good vision. Note the iris is dragged to the tube insertion. This may be avoided by performing a localized peripheral iridectomy and inserting the tube more posteriorly through the iridectomy so that the iris cannot adhere to the base of the tube. (Courtesy of James D. Brandt, MD)




Fig. 11: Exposed tube . A teenage female with uveitis underwent Baerveldt tube surgery for secondary glaucoma. However, the tube tunnel was very superficial and anterior; note the long tunnel within the corneal stroma. Although the plate was sutured to the sclera, the tube was not sutured against the sclera (e.g., with a box suture) and as a consequence bowed anteriorly. Over time, the donor scleral patch graft overlying the tube melted away and the tube eroded through the conjunctiva, and the patient presented complaining of pain and discomfort. (Courtesy of Cecilia Fenerty MD, FRCOphth)




Fig. 12: Developmentally delayed teen with glaucoma associated with Sturge-Weber syndrome returned years later with a history of eye rubbing. IOP control was good and there was no erosion, but the plate had moved forward from its original position by about 3 mm so the tube was too long and risked causing corneal endothelial damage. The tube was everted through a small corneal incision 1 mm anterior to the limbus and shortened to about 2 mm in length. IOP control was maintained. Note that the pupil is drawn toward the tube entry point, a common late-term finding in eyes with Sturge-Weber syndrome. (Courtesy of James D. Brandt, MD)

in pediatric glaucoma surgery [46]. Almost half of experts (44%) preferred GDDs as the primary surgical procedure in glaucoma following cataract surgery (GFCS), with 30% preferentially using GDDs in uveitic glaucoma. Most stated they would use GDDs after failed trabeculectomy (82%) with the AGV being the most popular choice (63%) followed by the BGI (41%). Only 15% preferred to augment their surgery with adjunctive antimetabolites, and most preferred AC tube placement unless contraindicated.

Table 4 is a compilation of published studies on pediatric GDDs in the published literature from 1984 to 2017 which the reader may find useful [9, 12, 22, 35–44, 47–72].

The published success rates of GDDs in pediatric glaucoma vary widely between 54% and 90% [28, 40, 43, 73]. This is due largely to differences in the age of the child, underlying diagnosis, variation in surgical technique, and device employed as well as differences in the authors' definitions of success and failure. Despite these limitations, a few general conclusions can be drawn. Firstly, although many studies report success rates around 80% after 1–2 years of follow-up [37, 74], longer-term studies consistently report a steady decline to ~50% success after 5 years of follow-up requiring reinstitution of medical therapy [22, 56, 59, 61, 73]. Secondly, while it is difficult to directly compare success rates between different GDDs, a number of studies have demonstrated equivalent results among devices [22, 51, 73, 75].

In most reported case series, GDDs have been reserved for use in refractory pediatric glaucoma of mixed etiology where other medical and surgical procedures have failed to optimally

Table 4: Published case series of glaucoma drainage devices in children, 1984–2017.

	Study	Location(s)	Diagnosis	Implant	Eyes (N)	Mean follow-up (months)	1 year success (%)
1984	Molteno [47]	Otago (NZ)	Mixed	SP Molteno™	83	66	73
1988	Minckler [48]	Doheny Eye Institute (Los Angeles)	Mixed	SP Molteno™	13	22.8	54
1989	Billson [49]	Sydney	Mixed	DP Molteno	23	41.3	78
1991	Hill [35]	Doheny Eye Institute (Los Angeles)	Mixed	SP + DP Molteno	65	22.7	62
1991	Munoz [50]	KKESH (Riyadh)	Mixed	SP Molteno	53	18	68
1992	Lloyd [36]	Doheny Eye Institute (Los Angeles)	Mixed	SP Molteno	16	49.1	56
1992	Nesher [41]	Florida and Washington Univ.	Mixed	SP + DP Molteno	27	20	57
1993	Netland [51]	MEEI	Mixed	AGV + BGI	20	25	80
1995	Fellenbaum [37]	Doheny Eye Institute (Los Angeles)	Mixed	BGI	30	15	86
1995	Siegner [52]	MEEI and Univ California, Davis	Mixed	BGI	15	13.6	80
1997	Coleman [12]	UCLA	Mixed	AGV	21	16.3 ± 11.2	78
1997	Eid [38]	Wills Eye Institute (Philadelphia)	Mixed	Mixed	18	47.3	72
1997	Donahue [42]	Iowa	Mixed	BGI	23	19	61
1998	Cunliffe [53]	Otago (NZ)	Mixed	SP + DP Molteno	34	134.4	85
1999	Englert [39]	Duke University	Mixed	AGV	27	12.6 ± 8.2	85
1999	Hamush [54]	UCLA	Sturge-Weber	AGV	11	30.4 ± 19.1	79
1999	Huang [55]	Multiple	Mixed	AGV	11	13.4	91
2001	Djodeyre [43]	Madrid	Mixed	AGV	35	12.6	70
2002	Pereira [44]	Wills Eye Institute (Philadelphia)	Mixed	Mixed	10	50	80
2003	Morad [40]	Toronto	Mixed	AGV	60	24.3 ± 16	93
2004	Budenz [56]	Miami & Univ. of California, Davis	Mixed	BGI	62	23.4 ± 21.7	80
2004	Rodrigues [57]	Brazil	PCG	Susanna	24	24	88
2005	Chen [58]	MEEI	Mixed	AGV	52	26 ± 20	85

continued...

...continued

2005	Rolim De Moura [59]	Doheny Eye Institute (Los Angeles), Univ. of Southern California	Mixed	BGI	48	median 21 (4–95)	91
2005	Kafkala [60]	MEEI	Uveitic	AGV	7	36.8 (6–60)	69.9 IOP reduction rate
2006	Van Overdam [61]	Netherlands	Mixed	BGI	55	32 (2–78)	94
2007	Autrata [62]	Czech Republic	Mixed	Molteno+ BGI	76	85 ± 78	91
2007	Souza [63]	UCLA	Mixed	AGV	78	61	80
2008	O'Malley Schotthoefer [22]	Duke Univ.	Mixed	AGV + BGI	70	66	92
2009	Sood [64]	Emory Univ.	Mixed	AGV + BGI	8	26.2 ± 9.5	75
2012	El Gendy [65]	USC	Mixed	BGI	20	46 ± 29	80
				AGV	11	33 ± 30	55
2014	Balekudaro [66]	India	Mixed	AGV	71	37.8 ± 32.1	97
2014	Razeghinejad [67]	Iran	PCG	AGV	33	32.6 ± 18.3	97
2014	Tai [68]	Univ. of Southern California	Mixed	BGI	45	??	87
2015	Chen [69]	UCLA	Mixed	AGV	119	73 ± 40	86
2015	Dave [70]	India	PCG	AGV	11	17.9 ± 9.3	91
2016	Mandalos [71]	United Kingdom	Mixed	Molteno+ BGI	69	45.7 ± 25.2	96
2017	Eksioglu [72]	Turkey	Uveitis	AGV	16	64.46 ± 33.56	56
2017	Vinod [9]	NYEEI	Mixed	PP BGI	37	78 ± 48.7	94.5

SP single plate, DP double plate, AGV Ahmed glaucoma valve, BGI Baerveldt® glaucoma implant, PCG primary congenital glaucoma, KKESH King Khaled Eye Specialist Hospital, MEEI Massachusetts Eye and Ear Infirmary, Boston, NYEEI New York Eye and Ear Infirmary

control IOP. Primary congenital glaucoma and secondary glaucoma particularly associated with aphakia form the bulk of cases analyzed. A small case series of GDDs in aniridia showed a success rate of up to 88% at 1 year [76]. The use of BGI [77] and AGV [54] in Sturge-Weber syndrome has also been shown to successfully improve IOP control in refractory cases, though meticulous hypotony prevention in the postoperative period is strongly advocated. A number of studies looking at surgical outcomes of GDDs in pediatric uveitic glaucoma have shown between 80% and 100% success rates up to 40 months of follow-up [60, 78, 79]. In these cases, however, GDDs of smaller surface areas were used to minimize the risk of hypotony. GDDs associated with corneal grafting procedures have demonstrated higher failure rates both in terms of IOP control and graft longevity [66], with higher complication rates particularly in simultaneous combined procedures [80]. Ideally, IOP should be controlled prior to considering corneal surgery. And while a pars plana approach may reduce corneal complications, it risks tube occlusion with vitreous.

While GDDs have demonstrated a high cumulative probability of long-term success, sight-threatening complications may occur at any stage postoperatively, requiring lifelong follow-up [71]. The most common complications relate either to hypotony or to the tube itself [28, 35, 37, 38, 43, 73, 81, 82].

Hypotony may occur at any stage during the early or late postoperative period, with the pediatric population at greater risk due to reduced scleral rigidity. The reported incidence of hypotony and flat AC varies, ranging from 0% to 25.7% in pediatric patients [12, 22, 34, 35, 37-41, 43, 50, 51, 73]. The results of different GDDs vary widely and are dependent on surgical technique and underlying diagnosis with underestimation also likely due to paucity of reliable IOP assessment in children. Early hypotony has been reported in AGVs to be as present in up to 7% of cases [66]. Rates of choroidal effusion range from 0% to 22% [12, 34, 35, 38-41, 43, 44, 53, 66, 73], while the most devastating complication of suprachoroidal hemorrhage has been documented to range from 0% to 13% [12, 34-38, 53, 73].

Tube-related complications are a heterogeneous group, encompassing erosion, occlusion, migration, iris or lens touch, and corneal decompensation related to corneal endothelial touch [73]. Interestingly, a recent retrospective comparative study of 69 pediatric eyes and 145 adult eyes found higher rates of corneal decompensating in the adult population occurring earlier in this group [83].

Tube migration and retraction may occur secondary to normalization or elevation of IOP, respectively, and tend to occur in younger patients with buphthalmic eyes. Rates of tube-cornea touch vary from 5.7% to 20% [37, 39, 40, 50, 73], with most identified cases requiring revision. Conversely, if tube retraction occurs, then a number of surgical options have been described including the use of a tube extender, a segment of 22-gauge intravenous catheter [84], or angio-catheter material [85].

Erosion of the tube or the scleral plate carries a significant risk of endophthalmitis and should be repaired immediately using a patch graft or where required explantation of the device in cases of plate erosion [74]. The reported incidence of erosion or extrusion of the tube or scleral plate ranges from 0% to 13% in pediatric patients [12, 34, 35, 37-44, 50, 51, 53, 56, 73]. Gedde and colleagues [86] noted that exposure of the tube was present in all cases of late-onset endophthalmitis

associated with the BGI. Early and late postoperative endophthalmitis rates associated with GDDs in children have been reported between 0% and 5% [12, 34, 35, 37, 38, 40–43, 50, 51, 53, 56, 73].

Motility issues and strabismus should also be considered in children particularly where binocularity is present [22]. The incidence of this complication ranges from 0% to 11% in children with various devices [12, 34, 37, 38, 40, 43, 51, 56, 87]. Permanent motility disorders represent a late complication and may be due to mechanical restriction of the extraocular muscles secondary to adhesion or scarring or to a large bleb or episcleral plate.

Options After Failed Surgery

Elevated IOP after GDD insertion may be due to either tube obstruction at either the tube tip or in the valve mechanism or GDD failure due to bleb encapsulation. A number of treatment options are available once GDDs fail to control IOP effectively either through plate fibrosis, scarring, or bleb encapsulation. Recommencement of topical glaucoma medications is the usual first-line option. Failing this, of the pediatric glaucoma experts surveyed [46], 26% would proceed with cyclodestruction, 26% would revise the GDD (capsule excision with or without anti-scarring agent), and 23% would insert a second GDD. A nonrandomized chart review of 17 eyes suggests that secondary cyclodestruction versus secondary GDD has equivocal results at 2 years [64]. The amount of cyclodestructive treatment required to achieve the desired degree of IOP reduction may be difficult to titrate and may be associated with high rates of retinal detachment, phthisis bulbi, and other vision-threatening complications [74]. Shah *et al.* demonstrated that after failed GDD, an additional GDD offered better IOP control than revision by excision of an encapsulated bleb [88]. A further retrospective case series of 22 eyes did not demonstrate higher-than-expected rates of complications associated with GDDs [89]; however, both these studies were in an adult population.

Conclusion

Glaucoma drainage devices are increasingly useful in the management of childhood glaucoma. They can be used as a primary procedure in certain situations or as a secondary procedure where more conventional surgery (e.g., angle surgery) has been carried out and failed. We hope that this chapter has provided a comprehensive review of why, when, and how GDDs should be used in the treatment of childhood glaucoma.

The reader may be excused for coming away from this chapter with some pessimism, especially after the main conclusion above that these devices have a 50% failure rate at 5 years. We believe it is important to put this in perspective, however. The eyes in which GDDs are generally used are those same eyes that would have almost certainly gone blind prior to the introduction of these devices and are best implanted sooner than later to optimize long-term visual prognosis. The authors have patients who maintain useful and sometimes excellent vision many years (even decades) after implantation in early childhood. We encourage those caring for children with glaucoma to add the use of GDDs to their surgical portfolio. This recommendation is

particularly important in resource-constrained settings now that low-cost GDDs are available worldwide. Successful GDD cases make all the hard work of managing these children among the most rewarding long-term aspect of childhood glaucoma care.

References

1. Barkan O. Operation for congenital glaucoma. *Am J Ophthalmol.* 1942;25(5):552–68.
2. Allen L, Burian HM. Trabeculotomy ab externo. A new glaucoma operation: technique and results of experimental surgery. *Am J Ophthalmol.* 1962;53:19–26.
3. Harms H, Dannheim R. Trabeculotomy 'ab externo'. *Trans Ophthalmol Soc U K.* 1970;89:589–90.
4. Minckler DS, Francis BA, Hodapp EA, Jampel HD, Lin SC, Samples JR, *et al.* Aqueous shunts in glaucoma: a report by the American Academy of ophthalmology. *Ophthalmology.* 2008;115(6):1089–98.
5. Britt MT, LaBree LD, Lloyd MA, Minckler DS, Heuer DK, Baerveldt G, *et al.* Randomized clinical trial of the 350-mm² versus the 500-mm² Baerveldt implant: longer term results: is bigger better? *Ophthalmology.* 1999;106(12):2312–8.
6. Gardiner BS, Smith DW, Coote M, Crowston JG. Computational Modeling of Fluid Flow and Intra-Ocular Pressure following Glaucoma Surgery *PLoS ONE.* 2010;5. (10) <https://doi.org/10.1371/journal.pone.0013178>. CrossRefPubMedCentralGoogle Scholar
7. Molteno AC. New implant for drainage in glaucoma. Clinical trial. *Br J Ophthalmol.* 1969;53(9):606–15.
8. Molteno AC, Polkinghorne PJ, Bowbyes JA. The vicryl tie technique for inserting a draining implant in the treatment of secondary glaucoma. *Aust N Z J Ophthalmol.* 1986;14(4):343–54.
9. Vinod K, Panarelli JF, Gentile RC, Sidoti PA. Long-term outcomes and complications of pars Plana Baerveldt implantation in children. *J Glaucoma.* 2017;26(3):266–71.
10. Heuer DK, Lloyd MA, Abrams DA, Baerveldt G, Minckler DS, Lee MB, *et al.* Which is better? One or two? A randomized clinical trial of single-plate versus double-plate Molteno implantation for glaucomas in aphakia and pseudophakia. *Ophthalmology.* 1992;99(10):1512–9.
11. Coleman AL, Hill R, Wilson MR, Choplin N, Kotas-Neumann R, Tam M, *et al.* Initial clinical experience with the Ahmed Glaucoma valve implant. *Am J Ophthalmol.* 1995;120(1):23–31.
12. Coleman AL, Smyth RJ, Wilson MR, Tam M. Initial clinical experience with the Ahmed Glaucoma valve implant in pediatric patients. *Arch Ophthalmol.* 1997;115(2):186–91.
13. Kaushik S, Kataria P, Raj S, Pandav SS, Ram J. Safety and efficacy of a low-cost glaucoma drainage device for refractory childhood glaucoma. *Br J Ophthalmol.* 2017;101(12):1623–7.
14. Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC, *et al.* Postoperative complications in the tube versus trabeculectomy (TVT) study during five years of follow-up. *Am J Ophthalmol.* 2012;153(5):804–14.
15. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL, *et al.* Treatment outcomes in the tube versus trabeculectomy (TVT) study after five years of follow-up. *Am J Ophthalmol.* 2012;153(5):789–803.
16. Swamynathan K, Capistrano AP, Cantor LB, WuDunn D. Effect of temporal corneal phacoemulsification on intraocular pressure in eyes with prior trabeculectomy with an antimetabolite. *Ophthalmology.* 2004;111(4):674–8.
17. Budenz DL, Barton K, Gedde SJ, Feuer WJ, Schiffman J, Costa VP, *et al.* Five-year treatment outcomes in the Ahmed Baerveldt comparison study. *Ophthalmology.* 2015;122(2):308–16.
18. Margeta MA, Kuo AN, Proia AD, Freedman SF. Staying away from the optic nerve: a formula for modifying glaucoma drainage device surgery in pediatric and other small eyes. *J AAPOS.* 2017;21(1):39–43.e1.
19. Suhr AW, Lim MC, Brandt JD, Izquierdo JC, Willits N. Outcomes of fornix-based versus limbus-based conjunctival incisions for glaucoma drainage device implant. *J Glaucoma.* 2012;21(8):523–9.

20. Cheng J, Abolhasani M, Beltran-Agullo L, Moss EB, Buys YM, Trope GE. Priming the Ahmed glaucoma valve: pressure required and effect of overpriming. *J Glaucoma*. 2015;24(4):e34–5.
21. Thakur S, Ichhpujani P, Kumar S. Grafts in glaucoma surgery: a review of the literature. *Asia Pac J Ophthalmol (Phila)*. 2017;6:469–76.
22. O'Malley Schotthoefer E, Yanovitch TL, Freedman SF. Aqueous drainage device surgery in refractory pediatric glaucomas: I. Long-term outcomes. *J AAPOS*. 2008;12(1):33–9.
23. Vinod K, Panarelli JF, Gentile RC, Sidoti PA. Vitreous occlusion of a Glaucoma drainage implant-surgical management. *J Glaucoma*. 2017;26(7):669–72.
24. Tarantola RM, Agarwal A, Lu P, Joos KM. Long-term results of combined endoscope-assisted pars plana vitrectomy and glaucoma tube shunt surgery. *Retina*. 2011;31(2):275–83.
25. Costa VP, Azuara-Blanco A, Netland PA, Lesk MR, Arcieri ES. Efficacy and safety of adjunctive mitomycin C during Ahmed glaucoma valve implantation: a prospective randomized clinical trial. *Ophthalmology*. 2004;111(6):1071–6.
26. Cui QN, Hsia YC, Lin SC, Stamper RL, Rose-Nussbaumer J, Mehta N, *et al*. Effect of mitomycin c and 5-fluorouracil adjuvant therapy on the outcomes of Ahmed glaucoma valve implantation. *Clin Exp Ophthalmol*. 2017;45(2):128–34.
27. Kirwan C, O'Keefe M, Lanigan B, Mahmood U. Ahmed valve drainage implant surgery in the management of paediatric aphakic glaucoma. *Br J Ophthalmol*. 2005;89:855–8.
28. Al-Mobarak F, Khan AO. Two-year survival of Ahmed valve implantation in the first 2 years of life with and without intraoperative mitomycin-C. *Ophthalmology*. 2009;116(10):1862–5.
29. Mahdy RA. Adjunctive use of bevacizumab versus mitomycin C with Ahmed valve implantation in treatment of pediatric glaucoma. *J Glaucoma*. 2011;20(7):458–63.
30. Nouri-Mahdavi K, Caprioli J. Evaluation of the hypertensive phase after insertion of the Ahmed Glaucoma valve. *Am J Ophthalmol*. 2003;136(6):1001–8.
31. Won HJ, Sung KR. Hypertensive phase following silicone plate Ahmed Glaucoma valve implantation. *J Glaucoma*. 2016;25(4):e313–7.
32. Law SK, Kornmann HL, Giaconci JA, Kwong A, Tran E, Caprioli J. Early aqueous suppressant therapy on hypertensive phase following Glaucoma drainage device procedure: a randomized prospective trial. *J Glaucoma*. 2016;25(3):248–57.
33. Pakravan M, Rad SS, Yazdani S, Ghahari E, Yaseri M. Effect of early treatment with aqueous suppressants on Ahmed glaucoma valve implantation outcomes. *Ophthalmology*. 2014;121(9):1693–8.
34. Hill R, Ohanesian R, Voskanyan L, Malayan A. The Armenian eye care project: surgical outcomes of complicated paediatric glaucoma. *Br J Ophthalmol*. 2003;87(6):673–6.
35. Hill RA, Heuer DK, Baerveldt G, Minckler DS, Martone JF. Molteno implantation for glaucoma in young patients. *Ophthalmology*. 1991;98(7):1042–6.
36. Lloyd MA, Sedlak T, Heuer DK, Minckler DS, Baerveldt G, Lee MB, *et al*. Clinical experience with the single-plate Molteno implant in complicated glaucomas. Update of a pilot study. *Ophthalmology*. 1992;99(5):679–87.
37. Fellenbaum PS, Sidoti PA, Heuer DK, Minckler DS, Baerveldt G, Lee PP. Experience with the baerveldt implant in young patients with complicated glaucomas. *J Glaucoma*. 1995;4(2):91–7.
38. Eid TE, Katz LJ, Spaeth GL, Augsburg JJ. Long-term effects of tube-shunt procedures on management of refractory childhood glaucoma. *Ophthalmology*. 1997;104(6):1011–6.
39. Englert JA, Freedman SF, Cox TA. The Ahmed valve in refractory pediatric glaucoma. *Am J Ophthalmol*. 1999;127(1):34–42.
40. Morad Y, Donaldson CE, Kim YM, Abdoell M, Levin AV. The Ahmed drainage implant in the treatment of pediatric glaucoma. *Am J Ophthalmol*. 2003;135(6):821–9.

41. Nesher R, Sherwood MB, Kass MA, Hines JL, Kolker AE. Molteno implants in children. *J Glaucoma*. 1992;1(4):228–32.
42. Donahue SP, Keech RV, Munden P, Scott WE. Baerveldt implant surgery in the treatment of advanced childhood glaucoma. *J AAPOS*. 1997;1(1):41–5.
43. Djodeyre MR, Peralta Calvo J, Abelairas GJ. Clinical evaluation and risk factors of time to failure of Ahmed glaucoma valve implant in pediatric patients. *Ophthalmology*. 2001;108(3):614–20.
44. Pereira ML, Araujo SV, Wilson RP, Azuara-Blanco A, Moster MR, Schmidt CM. Aqueous shunts for intractable glaucoma in infants. *Ophthalmic Surg Lasers*. 2002;33(1):19–29.
45. Joos KM, Lavina AM, Tawansy KA, Agarwal A. Posterior repositioning of glaucoma implants for anterior segment complications. *Ophthalmology*. 2001;108(2):279–84.
46. Papadopoulos M, Edmunds B, Chiang M, Mandal A, Grajewski AL, Khaw PT. Glaucoma surgery in children. In: Weinreb RN, Grajewski A, Papadopoulos M, Grigg J, Freedman S, editors. *Childhood glaucoma. WGA consensus series 9*. Amsterdam: Kugler Publications; 2013. p. 95–134.
47. Molteno AC, Ancker E, Van Biljon G. Surgical technique for advanced juvenile glaucoma. *Arch Ophthalmol*. 1984;102(1):51–7.
48. Minckler DS, Heuer DK, Hasty B, Baerveldt G, Cutting RC, Barlow WE. Clinical experience with the single-plate Molteno implant in complicated glaucomas. *Ophthalmology*. 1988;95(9):1181–8.
49. Billson F, Thomas R, Aylward W. The use of two-stage Molteno implants in developmental glaucoma. *J Pediatr Ophthalmol Strabismus*. 1989;26(1):3–8.
50. Munoz M, Tomey KF, Traverso C, Day SH, Senft SH. Clinical experience with the Molteno implant in advanced infantile glaucoma. *J Pediatr Ophthalmol Strabismus*. 1991;28(2):68–72.
51. Netland PA, Walton DS. Glaucoma drainage implants in pediatric patients. *Ophthalmic Surg*. 1993;24(11):723–9.
52. Siegner SW, Netland PA, Urban RC Jr, Williams AS, Richards DW, Latina MA, *et al*. Clinical experience with the Baerveldt glaucoma drainage implant. *Ophthalmology*. 1995;102(9):1298–307.
53. Cunliffe IA, Molteno AC. Long-term follow-up of Molteno drains used in the treatment of glaucoma presenting in childhood. *Eye (Lond)*. 1998;12(Pt 3a):379–85.
54. Hamush NG, Coleman AL, Wilson MR. Ahmed glaucoma valve implant for management of glaucoma in Sturge-weber syndrome. *Am J Ophthalmol*. 1999;128(6):758–60.
55. Huang MC, Netland PA, Coleman AL, Siegner SW, Moster MR, Hill RA. Intermediate-term clinical experience with the Ahmed glaucoma valve implant. *Am J Ophthalmol*. 1999;127(1):27–33.
56. Budenz DL, Gedde SJ, Brandt JD, Kira D, Feuer W, Larson E. Baerveldt glaucoma implant in the management of refractory childhood glaucomas. *Ophthalmology*. 2004;111(12):2204–10.
57. Rodrigues AM, Corpa MV, Mello PA, de Moura CR. Results of the Susanna implant in patients with refractory primary congenital glaucoma. *J AAPOS*. 2004;8(6):576–9.
58. Chen TC, Bhatia LS, Walton DS. Ahmed valve surgery for refractory pediatric glaucoma: a report of 52 eyes. *J Pediatr Ophthalmol Strabismus*. 2005;42(5):274–83. quiz 304–5
59. Rolim de Moura C, Fraser-Bell S, Stout A, Labree L, Nilfors M, Varma R. Experience with the baerveldt glaucoma implant in the management of pediatric glaucoma. *Am J Ophthalmol*. 2005;139(5):847–54.
60. Kafkala C, Hynes A, Choi J, Topalkara A, Foster CS. Ahmed valve implantation for uncontrolled pediatric uveitic glaucoma. *J AAPOS*. 2005;9(4):336–40.
61. van Overdam KA, de Faber JT, Lemij HG, de Waard PW. Baerveldt glaucoma implant in paediatric patients. *Br J Ophthalmol*. 2006;90(3):328–32.
62. Autrata R, Helmanova I, Oslejskova H, Vondracek P, Rehurek J. Glaucoma drainage implants in the treatment of refractory glaucoma in pediatric patients. *Eur J Ophthalmol*. 2007;17(6):928–37.
63. Souza C, Tran DH, Loman J, Law SK, Coleman AL, Caprioli J. Long-term outcomes of Ahmed glaucoma valve implantation in refractory glaucomas. *Am J Ophthalmol*. 2007;144(6):893–900.

64. Sood S, Beck AD. Cyclophotocoagulation versus sequential tube shunt as a secondary intervention following primary tube shunt failure in pediatric glaucoma. *J AAPOS*. 2009;13(4):379–83.
65. El Gendy NM, Song JC. Long term comparison between single stage Baerveldt and Ahmed glaucoma implants in pediatric glaucoma. *Saudi J Ophthalmol*. 2012;26(3):323–6.
66. Balekudaru S, Vadalkar J, George R, Vijaya L. The use of Ahmed glaucoma valve in the management of pediatric glaucoma. *J AAPOS*. 2014;18(4):351–6.
67. Razeghinejad MR, Kaffashan S, Nowroozzadeh MH. Results of Ahmed glaucoma valve implantation in primary congenital glaucoma. *J AAPOS*. 2014;18(6):590–5.
68. Tai AX, Song JC. Surgical outcomes of Baerveldt implants in pediatric glaucoma patients. *J AAPOS*. 2014;18(6):550–3.
69. Chen A, Yu F, Law SK, Giacony JA, Coleman AL, Caprioli J. Valved glaucoma drainage devices in pediatric glaucoma: retrospective long-term outcomes. *JAMA Ophthalmol*. 2015;133(9):1030–5.
70. Dave P, Senthil S, Choudhary N, Sekhar GC. Outcomes of Ahmed valve implant following a failed initial trabeculotomy and trabeculectomy in refractory primary congenital glaucoma. *Middle East Afr J Ophthalmol*. 2015;22(1):64–8.
71. Mandalos A, Tailor R, Parmar T, Sung V. The long-term outcomes of glaucoma drainage device in pediatric glaucoma. *J Glaucoma*. 2016;25(3):e189–95.
72. Eksioglu U, Yakin M, Sungur G, Satana B, Demirok G, Balta O, *et al*. Short- to long-term results of Ahmed glaucoma valve in the management of elevated intraocular pressure in patients with pediatric uveitis. *Can J Ophthalmol*. 2017;52(3):295–301.
73. Beck AD, Freedman S, Kammer J, Jin J. Aqueous shunt devices compared with trabeculectomy with mitomycin-C for children in the first two years of life. *Am J Ophthalmol*. 2003;136(6):994–1000.
74. Ishida K, Mandal AK, Netland PA. Glaucoma drainage implants in pediatric patients. *Ophthalmol Clin N Am*. 2005;18(3):431–42. vii
75. Tanimoto SA, Brandt JD. Options in pediatric glaucoma after angle surgery has failed. *Curr Opin Ophthalmol*. 2006;17(2):132–7.
76. Arroyave CP, Scott IU, Gedde SJ, Parrish RK, Feuer W. Use of glaucoma drainage devices in the management of glaucoma associated with aniridia. *Am J Ophthalmol*. 2003;135(2):155–9.
77. Budenz DL, Sakamoto D, Eliezer R, Varma R, Heuer DK. Two-staged Baerveldt glaucoma implant for childhood glaucoma associated with Sturge-weber syndrome. *Ophthalmology*. 2000;107(11):2105–10.
78. Bohnsack BL, Freedman SF. Surgical outcomes in childhood uveitic glaucoma. *Am J Ophthalmol*. 2013;155(1):134–42.
79. Valimaki J, Airaksinen PJ, Tuulonen A. Molteno implantation for secondary glaucoma in juvenile rheumatoid arthritis. *Arch Ophthalmol*. 1997;115(10):1253–6.
80. Al-Torbak AA. Outcome of combined Ahmed glaucoma valve implant and penetrating keratoplasty in refractory congenital glaucoma with corneal opacity. *Cornea*. 2004;23(6):554–9.
81. Nassiri N, Nouri-Mahdavi K, Coleman AL. Ahmed glaucoma valve in children: a review. *Saudi J Ophthalmol*. 2011;25(4):317–27.
82. Al-Torbak AA, Al-Shahwan S, Al-Jadaan I, Al-Hommadi A, Edward DP. Endophthalmitis associated with the Ahmed glaucoma valve implant. *Br J Ophthalmol*. 2005;89(4):454–8.
83. Mandalos A, Sung V. Glaucoma drainage device surgery in children and adults: a comparative study of outcomes and complications. *Graefes Arch Clin Exp Ophthalmol*. 2017;255(5):1003–11.
84. Bansal A, Fenerty CH. Extension of retracted glaucoma drainage tube using a 22-gauge intravenous catheter in complex pediatric glaucoma. *J Glaucoma*. 2010;19(4):248–51.
85. Smith MF, Doyle JW. Results of another modality for extending glaucoma drainage tubes. *J Glaucoma*. 1999;8(5):310–4.

86. Gedde SJ, Scott IU, Tabandeh H, Luu KK, Budenz DL, Greenfield D, *et al.* Late endophthalmitis associated with glaucoma drainage implants. *Ophthalmology*. 2001;108(7):1323–7.
87. Christmann LM, Wilson ME. Motility disturbances after Molteno implants. *J Pediatr Ophthalmol Strabismus*. 1992;29(1):44–8.
88. Shah AA, WuDunn D, Cantor L. Shunt revision versus additional tube shunt implantation after failed tube shunt surgery in refractory glaucoma. *Am J Ophthalmol*. 2000;129(4):455–60.
89. Burgoyne JK, WuDunn D, Lakhani V, Cantor L. Outcomes of sequential tube shunts in complicated glaucoma. *Ophthalmology*. 2000;107(2):309–14.

Source: Brandt J.D., Hammel N., Fenerty C., Karaconji T. (2018) Glaucoma Drainage Devices. In: Grajewski A., Bitrian E., Papadopoulos M., Freedman S. (eds) *Surgical Management of Childhood Glaucoma*. Springer, Cham. https://doi.org/10.1007/978-3-319-54003-0_7. © Springer Nature Switzerland AG 2018.

Bleb Wall Recession Technique to Repair Giant Bleb Formation After Ahmed Glaucoma Valve Implantation: A Case Report

Kaoru Manabe¹, Yoshifumi Ikeda², Etsuko Fujihara², Masaki Tanito^{1*}

Abstract

Background: Giant bleb formation after glaucoma tube shunt surgery is a rare condition and consensus regarding its management has not been established.

Case Presentation: A 66-year-old Japanese man with primary open-angle glaucoma underwent implantation of an Ahmed glaucoma valve to reduce the intraocular pressure in his left eye. At 4 weeks postoperatively, he presented with a foreign body sensation in his left eye. A slit-lamp examination revealed a giant conjunctival cyst at the superotemporal quadrant and dellen formation at the corneal limbus/conjunctiva adjacent to the anterior border of the giant cyst. Ocular pain was due to a giant bleb that bulged anteriorly from the Ahmed glaucoma valve plate. Eight days after the referral, he underwent surgery to reduce the bleb volume in his left eye. To recess the bleb, the anterior edge of the dissected bleb capsule was sutured using two interrupted 10–0 absorbable sutures back to the sclera to the anterior edge of the Ahmed glaucoma valve plate. Three months postoperatively, there was no bleb around the corneal limbus, but the bleb was present around the plate.

Conclusions: The surgical technique reported here can be an option to relieve dellen-associated ocular pain due to a bleb formed after tube shunt surgery.

Keywords: Giant bleb, Ahmed glaucoma valve, Primary open-angle glaucoma, Anterior segment optical coherence tomography, Surgical complication

*Correspondence: tanito-oph@umin.ac.jp

¹Department of Ophthalmology, Shimane University Faculty of Medicine, 89-1 Enya, Izumo, Shimane 693-8501, Japan.

²Division of Ophthalmology, Matsue Red Cross Hospital, Matsue, Japan.

Introduction

Formation of a giant bleb and the related ocular pain are rare complications after glaucoma tube shunt surgery; accordingly, no consensus regarding the management of this complication has been established. Here we report a case that was treated successfully by a bleb wall recession technique.

Case Presentation

Approval was obtained from the institutional review board of Matsue Red Cross Hospital and a written informed consent to undergo surgery and use of clinical data was provided by the patient preoperatively.

A 66-year-old Japanese man with primary open-angle glaucoma underwent implantation of an Ahmed glaucoma valve (AGV) (model FP-7, JFC Sales Plan Co., Ltd., Tokyo, Japan) to reduce the intraocular pressure (IOP) in his left eye (OS). On preoperative examination, the best-corrected visual acuity (BCVA) was 1.0 in his OS and the IOP was 22 mmHg despite instillation of a topical prostaglandin, β -blocker, and α 2 agonist after failed EX-PRESS® shunt (Alcon Japan, Tokyo, Japan) placed in the superonasal quadrant. The AGV plate was placed in the superotemporal quadrant, and the tube was inserted into the anterior chamber under a partial-thickness autologous scleral flap [1, 2]. No complications developed intraoperatively. Levofloxacin 1.5% (Nipro, Osaka Japan) and betamethasone 0.1% (Sanbetason; Santen Pharmaceutical) were applied topically four times daily for 3 weeks postoperatively. At 4 weeks postoperatively, he presented with a foreign body sensation in his OS.

At the referral, the BCVA and IOP were, respectively, 0.9 and 20 mmHg without glaucoma medication. A slit-lamp examination revealed a giant conjunctival cyst at the superotemporal quadrant (Fig. 1a) and dellen formation at the corneal limbus/conjunctiva adjacent to the anterior border of the giant cyst (Fig. 1b). Ocular pain was due to a giant bleb that bulged anteriorly from the AGV plate. Eight days after the referral, he underwent surgery to reduce the bleb volume in his OS (Additional file 1: Video 5). Under subconjunctival anesthesia using lidocaine 2%, a limbal peritomy was performed. The bleb capsule formed by Tenon tissue was dissected bluntly from the sclera and the conjunctiva (Fig. 1c). To recess the bleb, the anterior edge of the dissected bleb capsule was sutured using two interrupted 10–0 absorbable sutures (Vicryl, Johnson & Johnson, New Brunswick, NJ) back to the sclera to the anterior edge of the AGV plate (Fig. 1d, e). The conjunctiva was readapted with 10–0 Vicryl (Fig. 1f). Postoperatively, levofloxacin 1.5% and betamethasone 0.1% were applied topically four times daily for 3 weeks. One week postoperatively, the bleb size decreased, and the ocular pain resolved. Three months postoperatively, the BCVA and IOP were, respectively, 1.0 and 14 mmHg with three anti-glaucoma medications. A slit-lamp examination showed no bleb around the corneal limbus (Fig. 1g), but the bleb was present around the plate (Fig. 1h). Anterior segment optical coherence tomography (Casia 2, Tomey Corporation, Nagoya, Japan) showed no fluid accumulation around the tube (Fig. 1i); the anterior border of the bleb was restricted at the anterior edge of the plate (Fig. 1j). At the final




Fig. 9: Perioperative findings. Before surgical revision, a giant conjunctival cyst (a) and dellen formation (b) stained with fluorescein are observed in the superotemporal quadrant in the left eye. During the bleb recession revision surgery, bleb capsule is dissected bluntly from the sclera and the conjunctiva (c, arrow). The anterior edge of the dissected bleb capsule is re-fixed on the sclera using two interrupted 10-0 absorbable sutures at the anterior edge of the Ahmed glaucoma valve plate (d, e). The conjunctiva is readapted with 10-0 absorbable sutures (f). A slit-lamp observation at 3 months postoperatively shows the findings around the corneal limbus (g) and the Ahmed glaucoma valve plate (h). Anterior segment optical coherence tomography performed 3 months postoperatively shows the findings around the Ahmed glaucoma valve tube (i) and the plate (j). The red arrows indicate the anterior edge of the Ahmed glaucoma valve plate.

visit 6 months postoperatively, the BCVA and IOP were, respectively, 1.2 and 11 mmHg with three anti-glaucoma medications; a well-formed bleb was seen only around the AGV plate.

Discussion

The EX-PRESS® shunt and AGV were implanted in different quadrants; therefore, previous use of anti-metabolites during EX-PRESS® shunt surgery is unlikely to be associated with the giant bleb formation in this case. Previously, extension of a filtering bleb into the upper eyelid was reported in one case after Baerveldt glaucoma implant surgery [3], and in another case magnetic resonance imaging showed formation of a giant reservoir in the orbit after implantation of an AGV [4]. In previous large-scale clinical studies of tube shunt surgeries [5-7], no giant blebs were reported as a surgical complication. Thus, the current case of ocular pain due to formation of a giant bleb that caused dellen is unique in the literature. From this case, we learned that the wall of the bleb capsule can be dissected relatively easily from the conjunctiva and sclera, enabling surgical recession of the anterior border of the bleb.

Conclusion

The surgical technique reported here can be an option to relieve dellen-associated ocular pain due to formation of a bleb after tube shunt surgery.

Additional file: Additional file 1: Video S1. Surgical video of the bleb wall recession technique. (MP4 35099 kb)

Abbreviations: AGV: Ahmed glaucoma valve; BCVA: Best-corrected visual acuity; IOP: Intraocular pressure; OS: Left eye

Acknowledgements: None.

Authors' contributions: MT performed the surgery. KM and MT wrote the manuscript. All authors reviewed and approved the final manuscript.

Funding: None.

Availability of data and materials: All the relevant data are described in the manuscript

Ethics approval and consent to participate: The case was reported under approval from the institutional review board of Matsue Red Cross Hospital.

Consent for publication: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests: The authors declare that they have no competing interests.

References

1. Sano I, Tanito M, Uchida K, Katsube T, Kitagaki H, Ohira A. Assessment of filtration bleb and endplate positioning using magnetic resonance imaging in eyes implanted with long-tube glaucoma drainage devices. *PLoS One*. 2015;10:e0144595.
2. Tanito M, Sano I, Ikeda Y, Fujihara E. Patch grafting using an ologen collagen matrix to manage tubal exposure in glaucoma tube shunt surgery. *Case Rep Ophthalmol*. 2018;9:9–16.
3. Younger JR, Koener KS. Upper eyelid extension of a filtering bleb following glaucoma shunt surgery. *Ophthalmic Surg Lasers Imaging*. 2006;37:324–6.

4. Jeon TY, Kim HJ, Kim ST, Chung TY, Kee C. MR imaging features of giant reservoir formation in the orbit: an unusual complication of Ahmed glaucoma valve implantation. *AJNR. Am J Neurorad.* 2007;28:1565–6.
5. Budenz DL, Barton K, Feuer WJ, Schiffman J, Costa VP, Godfrey DG, Buys YM. Treatment outcomes in the Ahmed Baerveldt Comparison Study after 1 year of follow-up. *Ophthalmology.* 2011;118:443–52.
6. Christakis PG, Kalenak JW, Zurakowski D, Tsai JC, Kammer JA, Harasymowycz PJ, Ahmed II. The Ahmed Versus Baerveldt study: one-year treatment outcomes. *Ophthalmology.* 2011;118:2180–9.
7. Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Surgical complications in the Tube Versus Trabeculectomy Study during the first year of follow-up. *Am J Ophthalmol.* 2007;143:23–31.

Publisher's Note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Source: Manabe, K., Ikeda, Y., Fujihara, E. *et al.* Bleb wall recession technique to repair giant bleb formation after Ahmed Glaucoma Valve implantation: a case report. *J Med Case Reports* 13, 211 (2019). <https://doi.org/10.1186/s13256-019-2161-1>. © The Author(s). 2019.

[illegible]


In Primary Open Angle Glaucoma & Ocular Hypertension

^{Rx} **BRIMOLOL**

Brimonidine Tartrate 0.15% + Timolol Maleate 0.5%

■ **Combined power, Greater benefits** ■

BKC free BTFC offers comparable IOP lowering to BKC preserved BTFC^{1*}



- Single ocular instillation of BTFC without BKC showed statistically significant IOP reduction at 6 hrs. compared with baseline mean IOP value
- Maximum reduction in IOP observed at 2 hrs. following single instillation:
 - BTFC without BKC was 35.8%
 - BTFC with BKC was 32%

“ The efficacy of Brimonidine Tartrate 0.15% & Timolol Maleate 0.5% preserved with PHMB was comparable to reference item Brimolol® (BKC preserved)¹ ”

